CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
11702440,117024406,6,F,20151021,20190424,20151105,20190501,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-074328,BRISTOL MYERS SQUIBB,,31,YR,,M,Y,,,20190501,,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Bacterial sepsis;Renal failure,117024406,HO,,,117024406,1,20150527,20150916,,,117024406,1,Kaposi's sarcoma AIDS related
12326313,123263132,2,F,20130108,20190401,20160503,20190412,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-032890,BRISTOL MYERS SQUIBB,,69,YR,,M,Y,,,20190412,,MD,US,US,SUSTIVA,Anaphylactic reaction;Rash,123263132,OT,,,,,,,,,123263132,1,Product used for unknown indication
12657071,126570712,2,F,20150210,20160810,20160816,20190401,EXP,,US-GILEAD-2016-0224170,GILEAD,,52,YR,A,M,Y,75.28,KG,20190401,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal failure,126570712,OT,,,126570712,3,20140514,20160314,,,126570712,1,HIV infection
12845892,128458923,3,F,,20190617,20161013,20190624,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-083271,BRISTOL MYERS SQUIBB,,55,YR,,F,Y,,,20190624,,OT,IT,IT,EFAVIRENZ.,Lipodystrophy acquired,128458923,OT,,,128458923,1,200412,200605,,,128458923,1,Antiretroviral therapy
13343839,133438392,2,F,,20170307,20170316,20190524,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-023108,BRISTOL MYERS SQUIBB,,4,YR,,F,Y,,,20190524,,OT,US,ZA,EFAVIRENZ.,Petit mal epilepsy,133438392,OT,,,,,,,,,133438392,1,Antiretroviral therapy
13536066,135360663,3,F,,20190411,20170511,20190412,EXP,,DE-GILEAD-2017-0272168,GILEAD,"RADMER S, KASTIRR I, ADRESEN JR, ANDRESEN R. RESOLUTION OF RECURRENT BONE MARROW EDEMA AND INSUFFICIENCY FRACTURES IN AN HIV PATIENT FOLLOWING ANTIVIRAL THERAPY SWITCH. 2019 CONGRESS ON OSTEOLOGY GERMAN SOCIETY FOR OSTEOLOGY E.V. (DGO). 2019;UNK:28",62,YR,A,M,Y,,,20190412,,OT,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema;Foot fracture;Renal failure,135360663,OT,,,,,,,,,135360663,1,HIV infection
13565295,135652954,4,F,,20190617,20170519,20190625,EXP,,ZA-MYLANLABS-2017M1029650,MYLAN,,,,N,F,Y,,,20190625,,OT,ZA,ZA,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Corneal opacity congenital;Foetal exposure during pregnancy,135652954,CA,,,,,,,,,135652954,1,HIV infection
13581524,135815242,2,F,,20190405,20170525,20190415,EXP,,US-GLAXOSMITHKLINE-US2017GSK079150,GLAXOSMITHKLINE,"ALI MS, KOORAGAYALU S, MBA BI, OLSEN FC ET AL. ISOLATED MYOPATHY: AN UNUSUAL MANIFESTATION OF INHALED FLUTICASONE PROPIONATE AND RITONAVIR INTERACTION. ARCHIVOS DE BRONCONEUMOLOGIA. 2019;55(4):223-225 DOI.ORG/10.1016/J.ARBR",58,YR,,M,Y,,,20190415,,OT,US,US,EFAVIRENZ.,Aldolase increased;Drug interaction;Fall;Muscular weakness;Myopathy;Toxicity to various agents,135815242,HO,,,,,,,,,135815242,1,Chronic obstructive pulmonary disease
14026571,140265712,2,F,,20190422,20170929,20190507,EXP,,US-CIPLA LTD.-2017US17668,CIPLA,"ALI MS, KOORAGAYALU S, MBA BI, OLSEN FC. ISOLATED MYOPATHY: AN UNUSUAL MANIFESTATION OF INHALED FLUTICASONE PROPIONATE AND RITONAVIR INTERACTION.. ARCHIVOS DE BRONCONEUMOLOGIA. 2019;55 (4):223 TO 225",,,,,Y,,,20190507,,,COUNTRY NOT SPECIFIED,US,EFAVIRENZ.,Drug interaction;Fall;Myopathy;Toxicity to various agents,140265712,HO,,,,,,,,,140265712,1,Antiretroviral therapy
14175791,141757913,3,F,,20190408,20171109,20190410,EXP,,BG-GILEAD-2017-0303513,GILEAD,"YANCHEVA N, TEMELKOVA N, STRASHIMIROV D, GABARSKA I, TCHERVENYAKOVA T. ANTIRETROVIRAL THERAPY AND BONE HEALTH. ACTA MEDICA BULGARICA. 2019;46:5-10",45,YR,A,M,Y,,,20190410,,MD,BG,BG,EFAVIRENZ.,Osteoporosis,141757913,OT,,,,,,,,,141757913,1,HIV infection
14248948,142489486,6,F,,20190523,20171204,20190530,EXP,,GB-MYLANLABS-2017M1075159,MYLAN,,85,YR,,M,Y,,,20190530,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,142489486,OT,,,,,,,,,142489486,1,Cardiovascular event prophylaxis
14376262,143762623,3,F,20160216,20190510,20180111,20190516,EXP,,US-EXELIXIS-XL18418011920,EXELIXIS,,63,YR,,M,Y,112.7,KG,20190516,,MD,US,US,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR,Cerebrovascular accident,143762623,HO,,,143762623,1,20140121,,,,143762623,1,Kaposi's sarcoma
14379754,143797542,2,F,20171107,20190504,20180112,20190513,EXP,,GB-AUROBINDO-AUR-APL-2018-001814,AUROBINDO,,47,YR,,F,Y,,,20190513,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,143797542,OT,,,143797542,1,20170501,20171216,,,143797542,1,HIV infection
14494652,144946523,3,F,,20190604,20180206,20190617,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-006996,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20190617,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,144946523,CA,,,,,,,,,144946523,1,HIV infection
14608010,146080102,2,F,,20190314,20180307,20190530,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK038183,GLAXOSMITHKLINE,,52,YR,,M,Y,,,20190530,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,146080102,OT,,,,,,,,,146080102,1,HIV infection
14612446,146124462,2,F,,20190314,20180308,20190530,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2018GSK038183,VIIV,,52,YR,,M,Y,,,20190530,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,146124462,OT,,,,,,,,,146124462,1,HIV infection
14705555,147055553,3,F,,20190409,20180402,20190502,EXP,,US-ASTRAZENECA-2018SE39858,ASTRAZENECA,,,,,F,Y,68.5,KG,20190502,,,US,US,SUSTIVA,Chronic kidney disease;End stage renal disease;Renal injury,147055553,OT,,,147055553,1,200201,201601,,,,,
14711217,147112176,6,F,,20190430,20180403,20190507,EXP,,US-PFIZER INC-2018133712,PFIZER,,,,,M,Y,69,KG,20190507,,LW,US,US,SUSTIVA,Chronic kidney disease;End stage renal disease;Renal injury,147112176,OT,,,147112176,1,200201,201601,,,,,
14723192,147231922,2,F,,20190328,20180405,20190412,EXP,,US-TAKEDA-2018TUS008588,TAKEDA,,,,,,Y,,,20190412,,LW,US,US,SUSTIVA,Chronic kidney disease;End stage renal disease;Renal injury,147231922,OT,,,147231922,1,200201,201601,,,147231922,1,Product used for unknown indication
14800764,148007644,4,F,20001221,20190523,20180424,20190531,EXP,,FR-MYLANLABS-2018M1025782,MYLAN,,37,YR,,F,Y,,,20190531,,OT,US,FR,EFAVIRENZ.,Exposure during pregnancy;Gestational diabetes;Normal newborn,148007644,OT,,,148007644,1,19960814,,,,148007644,1,Antiretroviral therapy
14822044,148220442,2,F,,20190416,20180427,20190429,EXP,,GB-AUROBINDO-AUR-APL-2018-022247,AUROBINDO,,,,,,Y,,,20190429,,PH,GB,GB,EFAVIRENZ MILPHARM FILM-COATED TABLET,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,148220442,HO,,,148220442,1,20161004,20171215,,,148220442,1,HIV infection
14850446,148504463,3,F,,20190520,20180505,20190522,EXP,,FR-AUROBINDO-AUR-APL-2018-024204,AUROBINDO,,,,,,Y,,,20190522,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myositis,148504463,OT,,,,,,,,,148504463,1,HIV infection
15114149,151141496,6,F,20171006,20190610,20180706,20190624,EXP,,GB-AUROBINDO-AUR-APL-2018-033634,AUROBINDO,,,,,,Y,,,20190624,,OT,GB,GB,Efavirenz Film-coated Tablet,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,151141496,CA,,,151141496,1,20171006,20180205,,,151141496,1,HIV infection
15118575,151185752,2,F,,20180625,20180709,20190523,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-059819,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20190523,,OT,IT,IT,EFAVIRENZ.,Neurotoxicity;Toxicity to various agents,151185752,OT,,,,,,,,,151185752,1,HIV infection
15123625,1512362513,13,F,20180205,20190614,20180710,20190625,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-060524,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20190625,,MD,GB,GB,EFAVIRENZ.,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,1512362513,OT,,,1512362513,1,20171006,20180205,,,1512362513,1,HIV infection
15123626,1512362611,11,F,20171006,20190614,20180710,20190626,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063878,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190626,,OT,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,1512362611,OT,,,1512362611,1,20171006,20180205,,,1512362611,1,Product used for unknown indication
15124065,151240652,2,F,,20180625,20180710,20190523,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064218,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20190523,,OT,GB,IT,EFAVIRENZ.,Lipodystrophy acquired,151240652,OT,,,,,,,,,151240652,1,HIV infection
15124577,151245772,2,F,,20180625,20180710,20190523,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064219,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20190523,,OT,GB,IT,EFAVIRENZ.,Lipodystrophy acquired,151245772,OT,,,,,,,,,151245772,1,HIV infection
15144564,151445643,3,F,,20190419,20180713,20190429,EXP,,DE-MYLANLABS-2018M1031509,MYLAN,,43,YR,,F,Y,,,20190429,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Gene mutation;Viral mutation identified,151445643,OT,,,,,,,,,151445643,1,Product used for unknown indication
15152012,151520126,6,F,,20190507,20180717,20190517,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063262,BRISTOL MYERS SQUIBB,,,,N,F,Y,,,20190517,,CN,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly,151520126,CA,,,151520126,1,20110301,20180601,,,151520126,1,Product used for unknown indication
15158165,151581656,6,F,20171006,20190627,20180718,20190628,EXP,,GB-AUROBINDO-AUR-APL-2018-036078,AUROBINDO,,,,,,Y,,,20190628,,CN,GB,GB,Efavirenz Film-coated Tablet,Abortion spontaneous;Maternal exposure during pregnancy,151581656,OT,,,151581656,3,20171006,20180205,,,151581656,1,HIV infection
15214571,152145712,2,F,,20190510,20180730,20190523,EXP,,FR-VIIV HEALTHCARE LIMITED-B0561595B,VIIV,,,,N,,Y,,,20190523,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,152145712,DE,,,152145712,1,20050908,20050908,,,152145712,1,HIV infection
15238115,152381156,6,F,2014,20190518,20180803,20190601,EXP,,ES-AUROBINDO-AUR-APL-2018-039058,AUROBINDO,,,,,,Y,,,20190601,,OT,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,152381156,OT,,,152381156,1,2012,,,,152381156,1,HIV infection
15248149,152481496,6,F,,20190508,20180807,20190515,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-002639",BOEHRINGER INGELHEIM,,25,YR,,F,Y,,,20190515,,CN,FR,FR,EFAVIRENZ.,Insomnia;Maternal exposure during pregnancy;Vertigo,152481496,OT,,,152481496,1,20050704,20050908,,,152481496,1,HIV infection
15266655,152666552,2,F,20180706,20190417,20180810,20190418,EXP,,US-PFIZER INC-2018319211,PFIZER,,47,YR,,M,Y,40,KG,20190418,,OT,US,US,EFAVIRENZ.,Electrocardiogram QT prolonged,152666552,OT,,,152666552,1,20180309,20180706,,,152666552,1,Tuberculosis
15273902,152739022,2,F,,20190408,20180813,20190411,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-040296",BOEHRINGER INGELHEIM,,,,,,Y,,,20190411,,OT,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOP,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,152739022,CA,,,,,,,,,152739022,1,HIV infection
15335320,153353205,5,F,20060216,20190527,20180830,20190530,EXP,,PHHY2009FR075292,SANDOZ,,,,N,,Y,,,20190531,,CN,FR,FR,EFAVIRENZ.,Anencephaly;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,153353205,OT,,,153353205,1,20050523,20050908,,,153353205,1,Foetal exposure during pregnancy
15357443,153574433,3,F,20171006,20190522,20180906,20190531,EXP,GB-EMA-DD-20180827-ASHWINIHVP-120514,GB-NOVOPROD-619477,NOVO NORDISK,,43,YR,,F,Y,,,20190531,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,153574433,OT,,,153574433,5,20171006,20180205,,,153574433,1,Product used for unknown indication
15357909,153579092,2,F,20171006,20190508,20180906,20190515,EXP,,PHHY2018GB086977,SANDOZ,,43,YR,,F,Y,,,20190515,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,153579092,OT,,,153579092,4,20171006,20180205,,,153579092,1,Product used for unknown indication
15456648,154566485,5,F,,20190510,20181002,20190618,EXP,,GB-MYLANLABS-2018M1071213,MYLAN,,,,,F,Y,,,20190618,,PH,GB,GB,EFAVIRENZ.,Hypertension;Liver function test increased;Maternal exposure during breast feeding;Maternal exposure during pregnancy;Product use issue,154566485,OT,,,,,,,,,154566485,1,HIV infection
15456659,154566593,3,F,,20190325,20181002,20190402,EXP,,GB-MYLANLABS-2018M1071216,MYLAN,,,,I,,Y,,,20190402,,PH,GB,GB,EFAVIRENZ.,Exposure via breast milk;Foetal exposure during pregnancy;Polydactyly,154566593,CA,,,,,,,,,154566593,1,Product used for unknown indication
15473306,154733064,4,F,,20190620,20181008,20190627,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-089598,BRISTOL MYERS SQUIBB,,32,YR,,M,Y,,,20190627,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154733064,LT,,,,,,,,,154733064,1,Chronic hepatitis C
15480679,154806794,4,F,,20190501,20181010,20190507,EXP,,PHHY2009FR075290,SANDOZ,,25,YR,,F,Y,,,20190508,,CN,FR,FR,EFAVIRENZ.,Exposure during pregnancy;Folate deficiency;Insomnia;Vertigo,154806794,OT,,,154806794,1,20050513,20050908,,,154806794,1,HIV infection
15573679,155736793,3,F,,20190510,20181101,20190520,EXP,,CA-TEVA-2018-CA-968128,TEVA,,54,YR,,M,Y,,,20190520,,OT,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,155736793,OT,,,,,,,,,155736793,1,HIV infection
15615270,156152705,5,F,,20190404,20181114,20190408,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-103626,BRISTOL MYERS SQUIBB,,49,YR,,M,Y,,,20190408,,OT,PT,PT,EFAVIRENZ.,Acute kidney injury;Hepatotoxicity;Tubulointerstitial nephritis,156152705,OT,,,,,,,,,156152705,1,HIV infection
15617535,156175354,4,F,,20190408,20181114,20190411,EXP,,PHHY2018PT154439,SANDOZ,,49,YR,,M,Y,,,20190411,,OT,PT,PT,EFAVIRENZ.,Acute kidney injury;Hepatotoxicity;Tubulointerstitial nephritis,156175354,OT,,,,,,,,,156175354,1,HIV infection
15621336,156213363,3,F,2018,20190501,20181115,20190513,EXP,,UG-MYLANLABS-2018M1086706,MYLAN,,,,,M,Y,3.5,KG,20190513,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156213363,OT,,,156213363,1,20180709,,,,156213363,1,HIV infection
15622928,156229283,3,F,2018,20190501,20181115,20190513,EXP,,UG-MYLANLABS-2018M1086707,MYLAN,,,,,F,Y,3.69,KG,20190513,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156229283,CA,,,156229283,1,20180607,,,,156229283,1,Product used for unknown indication
15626751,156267513,3,F,,20190417,20181116,20190424,EXP,,CA-ABBVIE-18S-028-2552613-00,ABBVIE,,54,YR,,M,Y,,,20190424,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,156267513,OT,,,,,,,,,156267513,1,HIV infection
15627007,156270073,3,F,2018,20190501,20181116,20190510,EXP,,UG-MYLANLABS-2018M1086998,MYLAN,,0,YR,,F,Y,3.12,KG,20190510,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156270073,OT,,,156270073,1,20180301,,,,156270073,1,Product used for unknown indication
15645742,156457422,2,F,,20190610,20181121,20190615,EXP,,PHHY2018GB161759,SANDOZ,,,,,,Y,,,20190615,,OT,GB,GB,EFAVIRENZ.,Congenital toxoplasmosis;Foetal exposure during pregnancy,156457422,DE,,,,,,,,,156457422,1,HIV infection
15706512,157065122,2,F,,20190405,20181210,20190411,EXP,E2B_01280806,CA-SA-2018SA331431,SANOFI AVENTIS,UNK. UNK. UNK. UNK;UNK:UNK,46,YR,A,M,Y,,,20190411,,OT,CA,CA,EFAVIRENZ.,Drug interaction;Transaminases increased,157065122,OT,,,,,,,,,157065122,1,Pulmonary tuberculosis
15732856,157328562,2,F,201810,20190501,20181217,20190510,EXP,,ZA-MYLANLABS-2018M1093652,MYLAN,,,,,M,Y,.83,KG,20190510,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Intraventricular haemorrhage neonatal;Neonatal respiratory distress syndrome;Premature separation of placenta,157328562,OT,,,157328562,1,20181003,,,,157328562,1,HIV infection
15786142,157861422,2,F,20181020,20190429,20190103,20190510,EXP,,PG-JNJFOC-20181231772,JANSSEN,,27,YR,A,F,Y,45,KG,20190510,,MD,PG,PG,EFAVIRENZ.,Hepatotoxicity;Hypokalaemia;Optic neuritis,157861422,DS,,,157861422,1,20180905,20181214,,,157861422,1,Tuberculosis
15800297,158002972,2,F,,20190619,20190108,20190624,EXP,,CA-GILEAD-2019-0383284,GILEAD,,45,YR,A,M,Y,,,20190624,,OT,CA,CA,EFAVIRENZ.,Bone pain;Hypophosphataemia;Musculoskeletal deformity;Osteomalacia;Renal tubular dysfunction,158002972,DS,,,158002972,1,2007,,,,158002972,1,HIV infection
15801503,158015033,3,F,2018,20190501,20190109,20190510,EXP,,ZA-MYLANLABS-2019M1001015,MYLAN,,,,N,F,Y,2.86,KG,20190510,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy;Premature baby,158015033,OT,,,158015033,1,20180614,,,,158015033,1,Product used for unknown indication
15831626,158316262,2,F,20110920,20190409,20190116,20190425,EXP,,US-ASTRAZENECA-2018SF14892,ASTRAZENECA,,18417,DY,,M,Y,68,KG,20190425,,,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;End stage renal disease;Tubulointerstitial nephritis,158316262,OT,,,158316262,1,199811,201101,,,158316262,1,Gastrooesophageal reflux disease
15849719,158497193,3,F,2018,20190501,20190121,20190510,EXP,,ZA-MYLANLABS-2019M1004469,MYLAN,,0,YR,,M,Y,3.4,KG,20190510,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,158497193,CA,,,158497193,1,20180629,,,,158497193,1,Product used for unknown indication
15885693,158856932,2,F,20190116,20190503,20190129,20190510,EXP,,CA-TAIHO ONCOLOGY  INC-EU-2019-00249,TAIHO ONCOLOGY INC,,86,YR,,M,Y,50,KG,20190510,,CN,CA,CA,SUSTIVA,Disease progression,158856932,DE,,,158856932,1,20180808,20181228,,,158856932,1,Colorectal cancer metastatic
15886086,158860864,4,F,20090618,20190402,20190129,20190405,PER,,PHHY2018FR195297,SANDOZ,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL.. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T).. CHEMICAL BIOLOGY + DRUG DESIGN.. 2018;N/A:N/A. DOI:DOI: 10.1111/CBDD.13378",47,YR,,M,Y,,,20190405,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,158860864,OT,,,,,,,,,158860864,1,HIV infection
15934516,159345164,4,F,20050813,20190521,20190207,20190528,EXP,,FR-MYLANLABS-2019M1011150,MYLAN,,25,YR,,F,Y,,,20190528,,MD,FR,FR,EFAVIRENZ.,Insomnia;Maternal exposure during pregnancy;Vertigo,159345164,OT,,,159345164,1,20050523,20050908,,,159345164,1,HIV infection
15934528,159345283,3,F,,20190424,20190207,20190503,EXP,,FR-MYLANLABS-2019M1011151,MYLAN,,,,N,,Y,,,20190503,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,159345283,DE,,,159345283,1,20050513,20050908,,,159345283,1,Product used for unknown indication
15980666,159806664,4,F,20190209,20190404,20190219,20190411,EXP,,KZ-JNJFOC-20190215798,JANSSEN,,32,YR,A,M,Y,57.2,KG,20190411,,MD,KZ,KZ,EFAVIRENZ.,Diabetic ketoacidotic hyperglycaemic coma;Generalised tonic-clonic seizure;Hepatitis C;Hepatitis toxic;Intentional product use issue;Off label use;Sepsis;Tubulointerstitial nephritis,159806664,HO,,,159806664,1,20180525,20190209,,,159806664,1,Tuberculosis
15983366,159833662,2,F,,20190502,20190220,20190503,EXP,,IT-AUROBINDO-AUR-APL-2019-008587,AUROBINDO,,,,,,Y,,,20190503,,OT,IT,IT,EFAVIRENZ.,Drug interaction;Virologic failure,159833662,OT,,,,,,,,,159833662,1,HIV infection
16022512,160225122,2,F,,20190605,20190301,20190611,EXP,,CA-AUROBINDO-AUR-APL-2019-010641,AUROBINDO,,,,,,Y,,,20190611,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,160225122,OT,,,,,,,,,160225122,1,HIV infection
16024888,160248883,3,F,201701,20190408,20190301,20190417,EXP,,US-ASTRAZENECA-2018SF26393,ASTRAZENECA,,808,MON,,F,Y,68.9,KG,20190417,,,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;End stage renal disease;Hyperparathyroidism secondary;Nephrogenic anaemia;Renal failure;Renal injury,160248883,OT,,,160248883,1,20120729,20171231,,,160248883,1,Gastrooesophageal reflux disease
16032571,160325713,3,F,,20190416,20190304,20190429,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019003,BRISTOL MYERS SQUIBB,MENDEZ J. EVALUATION OF THE POPULATION OF COINFECTED HCV/HIV PATIENT NON RESPONDANT TO DAAS. PRESENTED AT CO-INFECTION PORTUGUESE STUDY GROUP. 2019,43,YR,,M,Y,,,20190429,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,160325713,OT,,,,,,,,,160325713,1,HIV test positive
16032642,160326423,3,F,20180116,20190401,20190305,20190414,EXP,,MZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-018776,BRISTOL MYERS SQUIBB,,44,YR,,F,Y,41,KG,20190414,,OT,MZ,MZ,EFAVIRENZ.,Encephalitis;Pathological fracture;Spinal cord injury,160326423,OT,,,160326423,1,20170411,20170411,,,160326423,1,HIV infection
16047905,160479052,2,F,,20190327,20190307,20190409,EXP,,GB-AMNEAL PHARMACEUTICALS-2019AMN00254,AMNEAL,"COCKBAIN B.C., MORA PERIS B., ABBARA A., SO C.W., COOKE G.. DISSEMINATED CMV INFECTION AND HLH IN A PATIENT WITH WELL-CONTROLLED HIV AND ULCERATIVE COLITIS. BMJ CASE REPORTS. 2019;12:2:E227916",50,YR,,M,Y,,,20190409,,MD,GB,GB,"Efavirenz, Emitricitabine, Tenofovir",Disseminated cytomegaloviral infection;Haemophagocytic lymphohistiocytosis,160479052,HO,,,,,,,,,160479052,1,Colitis ulcerative
16051764,160517642,2,F,,20190522,20190308,20190601,PER,,US-CELGENEUS-USA-20190209210,CELGENE,"ZARBAFIAN M, COTE B, RICHER V. TREATMENT OF MODERATE TO SEVERE PSORIASIS WITH APREMILAST OVER TWO YEARS IN THE CONTEXT OF LONG-TERM TREATED HIV INFECTION: A CASE REPORT. SAGE OPEN MEDICAL CASE REPORTS. 2019 MAR 01;.",54,YR,,M,Y,,,20190601,,OT,US,US,EFAVIRENZ.,Diarrhoea,,,,,,,,,,,160517642,1,Psoriasis
16052306,160523062,2,F,,20190514,20190308,20190524,EXP,,US-GLAXOSMITHKLINE-US2019040980,GLAXOSMITHKLINE,,,,,M,Y,,,20190524,,OT,US,US,SUSTIVA,Drug resistance,160523062,OT,,,,,,,,,160523062,1,HIV infection
16052308,160523082,2,F,,20190514,20190308,20190524,EXP,,US-VIIV HEALTHCARE LIMITED-US2019040980,VIIV,,,,,M,Y,,,20190524,,OT,US,US,SUSTIVA,Drug resistance,160523082,OT,,,,,,,,,160523082,1,HIV infection
16064738,160647383,3,F,20171006,20190429,20190312,20190503,EXP,,GB-MYLANLABS-2019M1022917,MYLAN,,43,YR,,F,Y,,,20190503,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,160647383,OT,,,160647383,1,20171006,20180205,,,160647383,1,HIV infection
16064851,160648512,2,F,2017,20190419,20190312,20190426,EXP,,US-ABBVIE-19K-163-2698768-00,ABBVIE,,69,YR,,M,Y,73.09,KG,20190426,,CN,US,US,SUSTIVA,Axillary mass;Axillary pain;Cataract;Decreased appetite;Localised infection;Mobility decreased;Neoplasm skin;Subcutaneous abscess;Weight increased;Wound secretion,160648512,OT,,,160648512,1,20150504,201901,,,160648512,1,Psoriatic arthropathy
16068384,160683842,2,F,,20190507,20190313,20190513,EXP,,CA-MYLANLABS-2019M1023388,MYLAN,,,,,,Y,,,20190513,,OT,CA,CA,Mylan-Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,160683842,OT,,,,,,,,,160683842,1,Prophylaxis against HIV infection
16100221,161002213,3,F,,20190402,20190321,20190413,EXP,,"DE-KADMON PHARMACEUTICALS, LLC-KAD201903-000177",KADMON,"ROCKSTROH J, WELZEL T, INGILIZ P, PETERSEN J, VAN DER VALK M, HERZER K. DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV IN PATIENTS COINFECTED WITH HIV: INTERIM RESULTS OF A MULTICENTER COMPASSIONATE USE PROGRAM. HEPATOLOGY. 2015;62 (SUPPL 1):728A-9A.",,,,,Y,,,20190412,,,COUNTRY NOT SPECIFIED,DE,EFAVIRENZ.,Abdominal pain;Acute kidney injury;Anaemia;Anal cancer;Arthralgia;Blood creatinine increased;Calculus urinary;Circulatory collapse;Clostridium difficile colitis;Dehydration;Dermatitis allergic;Diarrhoea;Drug withdrawal syndrome;Dyspnoea;Erysipelas;Fatigue;Fluid overload;Gastrointestinal disorder;Gastrointestinal infection;General physical health deterioration;Haemorrhoidal haemorrhage;Headache;Hepatic encephalopathy;Hepatic failure;Hepatobiliary disease;Hepatocellular carcinoma;Hypersensitivity vasculitis;Hypertension;Hyponatraemia;Infection;Lactic acidosis;Liver disorder;Lymphoedema;Mental disorder;Myocardial infarction;Nausea;Neoplasm;Neutropenia;Pancreatitis acute;Pancytopenia;Peritonitis;Peritonitis bacterial;Portal vein thrombosis;Sleep disorder;Soft tissue infection;Somnolence;Streptococcal sepsis;Vertigo,161002213,OT,,,,,,,,,161002213,1,Chronic hepatitis C
16119495,161194952,2,F,201004,20190515,20190326,20190521,EXP,,LT-VIIV HEALTHCARE LIMITED-LT2019GSK052951,VIIV,,42,YR,,M,Y,,,20190521,,MD,LT,LT,EFAVIRENZ.,Drug resistance;Extrapulmonary tuberculosis;Immune reconstitution inflammatory syndrome;Lymph node tuberculosis;Viraemia,161194952,OT,,,161194952,1,20100324,201110,,,161194952,1,Product used for unknown indication
16119505,161195052,2,F,201004,20190515,20190326,20190521,EXP,,LT-GLAXOSMITHKLINE-LT2019GSK052951,GLAXOSMITHKLINE,,42,YR,,M,Y,,,20190521,,MD,LT,LT,EFAVIRENZ.,Drug resistance;Extrapulmonary tuberculosis;Immune reconstitution inflammatory syndrome;Lymph node tuberculosis;Viraemia,161195052,HO,,,161195052,1,20100324,201110,,,161195052,1,Product used for unknown indication
16134897,161348972,2,F,,20190506,20190329,20190510,EXP,,PT-MYLANLABS-2019M1027766,MYLAN,"SUZUKI F, HOSAKA T, SUZUKI Y, SEZAKI H, AKUTA N, FUJIYAMA S, ET AL.. LONG-TERM OUTCOME OF ENTECAVIR TREATMENT OF NUCLEOS (T) IDE ANALOGUE-NA?VE CHRONIC HEPATITIS B PATIENTS IN JAPAN.. JOURNAL OF GASTROENTEROLOGY. 2018;1-2",32,YR,,M,Y,,,20190510,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,161348972,OT,,,,,,,,,161348972,1,HIV infection
16141046,161410461,1,I,,20190322,20190401,20190401,EXP,,PT-MYLANLABS-2019M1028492,MYLAN,"SUZUKI F, HOSAKA T, SUZUKI Y, SEZAKI H, AKUTA N, FUJIYAMA S, ET AL.. LONG-TERM OUTCOME OF ENTECAVIR TREATMENT OF NUCLEOS (T) IDE ANALOGUE-NAVE CHRONIC HEPATITIS B PATIENTS IN JAPAN.. JOURNAL OF GASTROENTEROLOGY. 2018;1-2",29,YR,,M,Y,,,20190401,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,161410461,LT,,,,,,,,,161410461,1,HIV infection
16143554,161435541,1,I,,20190326,20190401,20190401,EXP,,CA-PFIZER INC-2019136366,PFIZER,,,,,M,Y,,,20190401,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,161435541,OT,,,,,,,,,,,
16147793,161477931,1,I,,20190326,20190402,20190402,EXP,,CA-PFIZER INC-2019136429,PFIZER,,54,YR,,M,Y,,,20190402,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,161477931,OT,,,,,,,,,161477931,1,Bipolar disorder
16154342,161543421,1,I,,20190319,20190403,20190403,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2019-02941,ALKEM,"BUCCELLI C, VACCHIANO G, NIOLA M, GRAZIANO V, ET AL.. ON AN ENGAGED CASE OF CARDIAC ARRHYTHMIA FOLLOWING DULOXETINE INTOXICATION. ROM J LEG MED.. 2017;25:60-64",37,YR,,,Y,,,20190403,,OT,IT,US,EFAVIRENZ.,Completed suicide,161543421,DE,,,,,,,,,161543421,1,Product used for unknown indication
16154432,161544321,1,I,,20190331,20190403,20190403,EXP,,US-GILEAD-2019-0400328,GILEAD,,59,YR,A,M,Y,,,20190403,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow toxicity;Renal disorder,161544321,OT,,,,,,,,,161544321,1,HIV infection
16154442,161544421,1,I,,20190331,20190403,20190403,EXP,,US-GILEAD-2019-0400337,GILEAD,,65,YR,E,F,Y,,,20190403,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,161544421,OT,,,,,,,,,161544421,1,HIV infection
16155546,161555461,1,I,,20190320,20190404,20190404,EXP,,PT-AUROBINDO-AUR-APL-2019-017912,AUROBINDO,,,,,,Y,,,20190404,,OT,PT,PT,EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE,Exposure during pregnancy;Live birth;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,161555461,OT,,,,,,,,,161555461,1,HIV infection
16158034,161580341,1,I,,20190329,20190404,20190404,EXP,,GB-MYLANLABS-2019M1030655,MYLAN,,,,E,M,Y,,,20190404,,CN,GB,GB,EFAVIRENZ.,Death,161580341,DE,,,,,,,,,161580341,1,Product used for unknown indication
16158910,161589101,1,I,20110825,20181212,20190404,20190404,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-118425,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20190404,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,161589101,OT,,,,,,,,,161589101,1,HIV infection
16159047,161590471,1,I,,20190307,20190404,20190404,EXP,,GB-MYLANLABS-2019M1022572,MYLAN,,,,A,,Y,,,20190404,,MD,GB,GB,EFAVIRENZ/LAMIVUDINE/TENOFOVIR/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,161590471,OT,,,,,,,,,161590471,1,HIV infection
16162254,161622542,2,F,,20190506,20190405,20190514,EXP,,PT-MYLANLABS-2019M1031847,MYLAN,"SOARES J, SANTOS JV, SARMENTO A, COSTA-PEREIRA A.. SPONTANEOUS VIRAL CLEARANCE IN SIXTEEN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C.. INTERVIROLOGY. 2018;1-8",32,YR,,M,Y,,,20190514,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,161622542,OT,,,,,,,,,161622542,1,Hepatitis C
16170457,161704573,3,F,,20190429,20190408,20190506,EXP,,JP-SA-2019SA094965,SANOFI AVENTIS,"SAKURAI H., SASAO K., SUGAWARA Y., IRINO S., TAKEBE M., TSUCHIYA Y. ET.AL.. CONSCIOUSNESS DISTURBANCE WITH A FALSE POSITIVE OF TETRAHYDROCANNABINOL BY A DRUG URINE SCREENING IMMUNOASSAY: A CASE REPORT. KANTO JOURNAL OF JAPANESE ASSOCIATION FOR ACUTE MEDICINE (E-JOURNAL). 2018;39(2):307-10",67,YR,E,M,Y,,,20190506,,MD,JP,JP,EFAVIRENZ.,Altered state of consciousness;Atrophy;Hypercapnia;Loss of personal independence in daily activities;Respiratory acidosis;Respiratory depression;Respiratory failure;Respiratory muscle weakness,161704573,OT,,,,,,,,,161704573,2,HIV infection
16170692,161706921,1,I,,20190402,20190408,20190408,EXP,,AT-MYLANLABS-2019M1031449,MYLAN,"TAYLOR N, TOUZEAU V, GEIT M, GISINGER M, EGLE A, GREIL R, ET AL... RALTEGRAVIR IN PREGNANCY: A CASE SERIES PRESENTATION.. INTERNATIONAL JOURNAL OF STD + AIDS.. 2011;22(6):358-60",39,YR,,F,Y,,,20190408,,OT,AT,AT,EFAVIRENZ.,Acute stress disorder;Drug abuse;Exposure during pregnancy;Rebound effect;Viral load increased,161706921,OT,,,,,,,,,161706921,1,Antiretroviral therapy
16172812,161728121,1,I,,20181204,20190409,20190409,PER,,UG-LUPIN PHARMACEUTICALS INC.-2018-08630,LUPIN,,,,,,Y,,,20190409,,OT,UG,UG,EFAVIRENZ.,Rash,,,,,,,,,,,161728121,1,Antibiotic therapy
16172826,161728261,1,I,,20181204,20190409,20190409,PER,,UG-LUPIN PHARMACEUTICALS INC.-2018-08625,LUPIN,,,,,,Y,,,20190409,,OT,UG,UG,EFAVIRENZ.,Vomiting,,,,,,,,,,,161728261,1,Antibiotic therapy
16172857,161728571,1,I,,20181204,20190409,20190409,PER,,UG-LUPIN PHARMACEUTICALS INC.-2018-08624,LUPIN,,,,,,Y,,,20190409,,OT,UG,UG,EFAVIRENZ.,Hypersensitivity,161728571,OT,,,,,,,,,161728571,1,Antiretroviral therapy
16172859,161728591,1,I,,20181204,20190409,20190409,PER,,UG-LUPIN PHARMACEUTICALS INC.-2018-08629,LUPIN,,,,,,Y,,,20190409,,OT,UG,UG,EFAVIRENZ.,Rash maculo-papular,,,,,,,,,,,161728591,1,Antibiotic therapy
16172860,161728602,2,F,,20190429,20190409,20190514,PER,,UG-LUPIN PHARMACEUTICALS INC.-2018-08632,LUPIN,,,,,,Y,,,20190514,,OT,UG,UG,EFAVIRENZ.,Aphthous ulcer,,,,,,,,,,,161728602,1,Antiretroviral therapy
16177078,161770781,1,I,,20190401,20190409,20190409,EXP,,ZA-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-204432,RANBAXY,,,,,F,Y,,,20190409,,CN,ZA,ZA,ASPEN EFAVIRENZ,Dyspnoea,161770781,DE,,,161770781,1,201810,,,,161770781,1,Dyspepsia
16181512,161815121,1,I,,20190404,20190410,20190410,EXP,,BW-GLAXOSMITHKLINE-BW2019GSK060518,GLAXOSMITHKLINE,"RWEGERERA GM, RAMOLEFHE TT, NGOY NA, LESIAMANG M, RI VERA YP. SALMONELLA SEPSIS AND URINARY TRACT INFECTION COMPLICATING WITH ACUTE KIDNEY INJURY IN A HIV POSITIVE FEMALE PATIENT. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 2019;13 (3):OD11-OD12 DOI: 10.7860/JCDR/20",44,YR,,F,Y,67,KG,20190410,,MD,BW,BW,EFAVIRENZ.,Treatment noncompliance;Virologic failure,161815121,OT,,,,,,,,,161815121,1,HIV infection
16181632,161816321,1,I,,20190404,20190410,20190410,EXP,,BW-VIIV HEALTHCARE LIMITED-BW2019GSK060518,VIIV,"RWEGERERA GM, RAMOLEFHE TT, NGOY NA, LESIAMANG M, RI VERA YP. SALMONELLA SEPSIS AND URINARY TRACT INFECTION COMPLICATING WITH ACUTE KIDNEY INJURY IN A HIV POSITIVE FEMALE PATIENT. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 2019;13 (3):OD11-OD12 DOI: 10.7860/JCDR/20",44,YR,,F,Y,67,KG,20190410,,MD,BW,BW,EFAVIRENZ.,Treatment noncompliance;Virologic failure,161816321,OT,,,,,,,,,161816321,1,HIV infection
16182683,161826831,1,I,,20190403,20190411,20190411,EXP,,IN-CIPLA LTD.-2019IN01856,CIPLA,,,,,,Y,,,20190411,,OT,IN,IN,EFAVIRENZ.,Jaundice,161826831,OT,,,,,,,,,161826831,1,HIV infection
16182869,161828692,2,F,,20190401,20190411,20190412,EXP,,UG-CIPLA LTD.-2019UG01819,CIPLA,"SSEBAMBULIDDE K, SEGAWA I, LAKER E, LAMORDE M, CASTELNOUVO B, NAKASUJJA N ET AL.. SYMPTOMATIC CEREBROSPINAL FLUID HIV-1 ESCAPE IN TWO PATIENTS ON SECOND-LINE ANTIRETROVIRAL THERAPY IN UGANDA. OXFORD MEDICAL CASE REPORTS. 2019;2:79 TO 82",,,,,Y,,,20190412,,OT,UG,UG,EFAVIRENZ.,Treatment noncompliance;Virologic failure,161828692,OT,,,,,,,,,161828692,1,HIV infection
16183901,161839011,1,I,,20190405,20190411,20190411,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-015928",BOEHRINGER INGELHEIM,,52,YR,,M,Y,,,20190411,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,161839011,OT,,,,,,,,,161839011,1,HIV infection
16185726,161857261,1,I,,20190401,20190411,20190411,EXP,,ZA-GILEAD-2019-0400485,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Low birth weight baby,161857261,OT,,,,,,,,,161857261,1,HIV infection
16186606,161866061,1,I,,20190401,20190411,20190411,EXP,,ZA-GILEAD-2019-0401093,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Microcephaly,161866061,OT,,,,,,,,,161866061,1,HIV infection
16186618,161866181,1,I,,20190401,20190411,20190411,EXP,,ZA-GILEAD-2019-0401788,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Microcephaly,161866181,OT,,,,,,,,,161866181,1,HIV infection
16186720,161867201,1,I,,20190401,20190411,20190411,EXP,,ZA-GILEAD-2019-0401790,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Microcephaly,161867201,OT,,,,,,,,,161867201,1,HIV infection
16186723,161867231,1,I,,20190401,20190411,20190411,EXP,,ZA-GILEAD-2019-0401796,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Microcephaly,161867231,OT,,,,,,,,,161867231,1,HIV infection
16186724,161867241,1,I,,20190401,20190411,20190411,EXP,,ZA-GILEAD-2019-0401789,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Microcephaly,161867241,OT,,,,,,,,,161867241,1,HIV infection
16186725,161867251,1,I,,20190401,20190411,20190411,EXP,,ZA-GILEAD-2019-0401792,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Microcephaly,161867251,OT,,,,,,,,,161867251,1,HIV infection
16186726,161867261,1,I,,20190401,20190411,20190411,EXP,,ZA-GILEAD-2019-0401791,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Microcephaly,161867261,OT,,,,,,,,,161867261,1,HIV infection
16186727,161867271,1,I,,20190401,20190411,20190411,EXP,,ZA-GILEAD-2019-0401797,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Microcephaly,161867271,OT,,,,,,,,,161867271,1,HIV infection
16186735,161867351,1,I,,20190401,20190411,20190411,EXP,,ZA-GILEAD-2019-0401793,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Microcephaly,161867351,OT,,,,,,,,,161867351,1,HIV infection
16186736,161867361,1,I,,20190401,20190411,20190411,EXP,,ZA-GILEAD-2019-0401794,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Microcephaly,161867361,OT,,,,,,,,,161867361,1,HIV infection
16186737,161867371,1,I,,20190401,20190411,20190411,EXP,,ZA-GILEAD-2019-0401795,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20190411,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Microcephaly,161867371,OT,,,,,,,,,161867371,1,HIV infection
16187920,161879201,1,I,,20181102,20190412,20190412,EXP,,IN-ALKEM LABORATORIES LIMITED-IN-ALKEM-2018-12081,ALKEM,,39,YR,,M,Y,,,20190412,,OT,GB,IN,EFAVIRENZ.,Drug ineffective;Therapy partial responder,161879201,OT,,,,,,,,,161879201,1,Bipolar disorder
16189076,161890761,1,I,20171006,20190401,20190412,20190412,EXP,,GB-APOTEX-2019AP011295,APOTEX,,16,WK,,M,Y,,,20190412,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,161890761,DE,,,161890761,2,20171006,20180205,,,161890761,1,Product used for unknown indication
16196049,161960491,1,I,20110523,20190401,20190415,20190415,EXP,,IT-AUROBINDO-AUR-APL-2019-019629,AUROBINDO,,,,,,Y,,,20190415,,MD,IT,IT,EFAVIRENZ.,Nervous system disorder;Renal impairment,161960491,OT,,,161960491,1,20150730,20110523,,,161960491,1,HIV infection
16196923,161969231,1,I,20190311,,20190311,20190311,DIR,,,FDA-CTU,,59,YR,,M,N,,,20190311,N,PH,US,US,EFAVIRENZ TAB 600MG,Blood cholesterol increased,,,161969231,HP,161969231,1,200403,,,,,,
16198926,161989261,1,I,,20190409,20190415,20190415,EXP,,FR-MYLANLABS-2019M1034886,MYLAN,,,,A,F,Y,,,20190415,,MD,FR,FR,EFAVIRENZ.,Blood HIV RNA increased;Drug ineffective,161989261,OT,,,161989261,1,200308,200507,,,161989261,1,HIV infection
16201453,162014531,1,I,20110523,20190402,20190416,20190416,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-033631,BRISTOL MYERS SQUIBB,,50,YR,,M,Y,80,KG,20190416,,MD,IT,IT,EFAVIRENZ.,Nervous system disorder;Neurotoxicity;Renal impairment,162014531,OT,,,162014531,1,20110420,20110523,,,162014531,1,HIV infection
16202935,162029351,1,I,,20190406,20190416,20190416,EXP,,UG-MYLANLABS-2019M1035391,MYLAN,"MUNDERI P, WERE E, AVIHINGSANON A, ABENA MESSOMO MBIDA P, MOHAPI L, SAMBA BM, ET AL. SALIF TRIAL: SWITCHING SUPPRESSED FIRST-LINE PATIENTS TO TENOFOVIR/EMTRICITABINE/RILPIVIRINE (TDF/FTC/RPV) IS NON-INFERIOR TO TDF/FTC/EFAVIRENZ (TDF/FTC/EFV) AND COULD BE AN ALTERNATIVE TREATMENT OPTION IN LMICS. J-INT-AIDS-SOC 2016;19 (SUPPL. 5)(6):76-77 ABSTR. THAB0104.",,,A,,Y,,,20190416,,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,162029351,OT,,,,,,,,,162029351,1,HIV infection
16204531,162045311,1,I,,20190307,20190416,20190416,EXP,,GB-MYLANLABS-2019M1022557,MYLAN,,,,A,,Y,,,20190416,,MD,GB,GB,EFAVIRENZ/LAMIVUDINE/TENOFOVIR/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,162045311,OT,,,,,,,,,162045311,1,HIV infection
16206633,162066331,1,I,,20190402,20190417,20190417,EXP,,CA-AUROBINDO-AUR-APL-2019-019815,AUROBINDO,,,,,,Y,,,20190417,,OT,CA,CA,EFAVIRENZ.,Depression;Drug interaction,162066331,OT,,,,,,,,,162066331,1,Product used for unknown indication
16208651,162086511,1,I,,20190412,20190417,20190417,EXP,,CA-GILEAD-2019-0402293,GILEAD,,48,YR,A,M,Y,,,20190417,,CN,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased;Osteoporosis,162086511,OT,,,162086511,1,2009,2012,,,162086511,1,HIV infection
16209032,162090321,1,I,,20190408,20190417,20190417,EXP,,US-VIIV HEALTHCARE LIMITED-KE2019GSK066516,VIIV,,,,A,F,Y,,,20190417,,OT,US,KE,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,162090321,OT,,,,,,,,,162090321,1,HIV infection
16209033,162090331,1,I,,20190408,20190417,20190417,EXP,,US-GLAXOSMITHKLINE-KE2019GSK066516,GLAXOSMITHKLINE,,,,A,F,Y,,,20190417,,OT,US,KE,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,162090331,OT,,,,,,,,,162090331,1,HIV infection
16213600,162136001,1,I,,20190405,20190418,20190418,EXP,,CA-MYLANLABS-2019M1038079,MYLAN,,,,,M,Y,,,20190418,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction,162136001,OT,,,,,,,,,162136001,1,Product used for unknown indication
16216393,162163931,1,I,,20190410,20190419,20190419,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-037133,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190419,,CN,AU,AU,EFAVIRENZ.,Hyperbilirubinaemia;Proteinuria;Renal impairment,162163931,OT,,,,,,,,,162163931,1,Product used for unknown indication
16217278,162172781,1,I,,20190415,20190419,20190419,EXP,,UG-STRIDES ARCOLAB LIMITED-2019SP003294,STRIDES,"SSEBAMBULIDDE K, SEGAWA I, LAKER E, LAMORDE M, CASTELNOUVO B, NAKASUJJA N, ET AL. SYMPTOMATIC CEREBROSPINAL FLUID HIV-1 ESCAPE IN TWO PATIENTS ON SECOND-LINE ANTIRETROVIRAL THERAPY IN UGANDA. OXF- MED-CASE-REPORTS. 2019;2019(2):79-82",62,YR,,M,Y,,,20190419,,OT,UG,UG,EFAVIRENZ.,Drug resistance;Viral mutation identified;Virologic failure,162172781,OT,,,,,,,,,162172781,1,HIV infection
16224805,162248051,1,I,,20190411,20190422,20190422,EXP,,GB-MYLANLABS-2019M1036931,MYLAN,,,,A,F,Y,,,20190422,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kidney infection,162248051,OT,,,,,,,,,162248051,1,Product used for unknown indication
16229775,162297751,1,I,200401,20190417,20190423,20190423,EXP,,ES-GILEAD-2019-0403238,GILEAD,,68,YR,E,M,Y,69.5,KG,20190423,,MD,ES,ES,EFAVIRENZ.,Acute myocardial infarction;Diabetes mellitus;Hepatomegaly;Hypertension,162297751,OT,,,162297751,1,200311,200805,,,162297751,1,HIV infection
16231775,162317751,1,I,,20190417,20190424,20190424,EXP,,CA-ABBVIE-19S-028-2752397-00,ABBVIE,,52,YR,,M,Y,,,20190424,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,162317751,OT,,,,,,,,,162317751,1,HIV infection
16236751,162367512,2,F,,20190422,20190425,20190506,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-19-02577,HIKMA,"ALI M, KOORAGAYALU S, MBA B, OLSEN F. ISOLATED MYOPATHY: AN UNUSUAL MANIFESTATION OF INHALED FLUTICASONE PROPIONATE AND RITONAVIR INTERACTION. ARCHIVOS DE BRONCONEUMOLOGIA. 2019;55(4):223-225.",58,YR,,M,Y,,,20190506,,MD,US,US,EFAVIRENZ.,Drug interaction;Fall;Myopathy;Toxicity to various agents,162367512,HO,,,,,,,,,162367512,1,HIV infection
16246219,162462191,1,I,,20190419,20190426,20190426,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-040062,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190426,,MD,US,US,EFAVIRENZ.,Drug hypersensitivity,,,,,,,,,,,162462191,1,Product used for unknown indication
16246275,162462752,2,F,200809,20190428,20190426,20190509,EXP,,ES-GILEAD-2019-0403239,GILEAD,,68,YR,E,M,Y,69.5,KG,20190509,,MD,ES,ES,EFAVIRENZ.,Pulmonary tuberculosis,162462752,OT,,,162462752,1,200805,200905,,,162462752,1,HIV infection
16251297,162512973,3,F,20050813,20190528,20190429,20190604,EXP,,FR-GILEAD-2019-0404516,GILEAD,,,,N,,Y,,,20190604,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,162512973,OT,,,162512973,1,20050523,20050908,,,162512973,1,HIV infection
16252625,162526251,1,I,,20190419,20190429,20190429,EXP,,GB-MYLANLABS-2019M1040011,MYLAN,,,,A,M,Y,,,20190429,,MD,GB,GB,EFAVIRENZ.,Diabetes mellitus;Disease risk factor;Hypertension;Renal impairment,162526251,OT,,,,,,,,,162526251,1,HIV infection
16256776,162567761,1,I,,20190422,20190430,20190430,EXP,,CN-GLAXOSMITHKLINE-CN2019075869,GLAXOSMITHKLINE,PAN X. SHORT COMMUNICATION: DISCORDANCE OF HIV-1 VIRAL LOAD FROM PAIRED BLOOD AND SEMINAL PLASMA SAMPLES IN A CHINESE MEN WHO HAVE SEX WITH MEN POPULATION.. AIDS RESEARCH AND HUMAN RETROVIRUSES.. 2019;35 (4):393-395,49,YR,,M,Y,,,20190430,,OT,CN,CN,EFAVIRENZ.,Drug ineffective;Viral load increased,162567761,OT,,,,,,,,,162567761,1,HIV infection
16256778,162567781,1,I,,20190422,20190430,20190430,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019075869,VIIV,PAN X. SHORT COMMUNICATION: DISCORDANCE OF HIV-1 VIRAL LOAD FROM PAIRED BLOOD AND SEMINAL PLASMA SAMPLES IN A CHINESE MEN WHO HAVE SEX WITH MEN POPULATION.. AIDS RESEARCH AND HUMAN RETROVIRUSES.. 2019;35 (4):393-395,49,YR,,M,Y,,,20190430,,OT,CN,CN,EFAVIRENZ.,Drug ineffective;Viral load increased,162567781,OT,,,,,,,,,162567781,1,HIV infection
16256971,162569711,1,I,,20190417,20190430,20190430,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-039675,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190430,,PH,DE,DE,SUSTIVA,Adverse event;Off label use,162569711,HO,,,,,,,,,162569711,1,HIV infection
16257267,162572672,2,F,,20190508,20190430,20190510,EXP,,FR-ABBVIE-19S-056-2762980-00,ABBVIE,,,,,,Y,,,20190510,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,162572672,DE,,,,,,,,,162572672,1,Maternal exposure timing unspecified
16257946,162579461,1,I,,20190422,20190430,20190430,EXP,,BR-MYLANLABS-2019M1039917,MYLAN,,24,YR,,F,Y,,,20190430,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Anembryonic gestation;Maternal exposure during pregnancy,162579461,OT,,,162579461,1,20170609,20171231,,,162579461,1,HIV infection
16258145,162581451,1,I,,20190423,20190430,20190430,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK074257,GLAXOSMITHKLINE,,,,,,Y,,,20190430,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162581451,OT,,,,,,,,,162581451,1,HIV infection
16258147,162581471,1,I,,20190423,20190430,20190430,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK074257,VIIV,,,,,,Y,,,20190430,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162581471,OT,,,,,,,,,162581471,1,HIV infection
16261847,162618472,2,F,,20190506,20190501,20190508,EXP,,CA-GILEAD-2019-0405133,GILEAD,,,,I,,Y,,,20190508,,OT,CA,CA,EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL MALEATE,Atrial septal defect;Ventricular septal defect,162618472,OT,,,,,,,,,162618472,1,HIV infection
16263806,162638061,1,I,,20190417,20190502,20190502,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-039739,BRISTOL MYERS SQUIBB,,,,,M,Y,88.44,KG,20190502,,CN,US,US,SUSTIVA,Adverse event,,,,,162638061,1,2000,,,,162638061,1,HIV infection
16264201,162642011,1,I,201404,20181219,20190502,20190502,EXP,IT-EMA-DD-20180724-TANEJAEVHP-112149,IT-MYLANLABS-2018M1095832,MYLAN,"TARTAGLIA A, FERRARA SM, SICA S, SANTANTONIO T.. SUCCESSFUL TREATMENT WITH TENOFOVIR ALAFENAMIDE OF A HIV/HEPATITIS B VIRUS COINFECTED PATIENT WITH HIV AND HEPATITIS B VIRUS DRUG RESISTANCE, END-STAGE RENAL DISEASE ON HAEMODIALYSIS.. AIDS. 2017;31(16):2314-2315",27,YR,,F,Y,,,20190502,,OT,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Pathogen resistance;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,162642011,OT,,,162642011,5,201505,201404,,,162642011,1,HIV infection
16266600,162666003,3,F,20181214,20190605,20190502,20190606,EXP,,BR-GILEAD-2019-0405171,GILEAD,,23,YR,A,F,Y,,,20190606,,OT,BR,BR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,162666003,OT,,,162666003,1,20181214,,,,162666003,1,HIV infection
16266686,162666862,2,F,20181214,20190520,20190502,20190522,EXP,,BR-GILEAD-2019-0405383,GILEAD,,,,,F,Y,,,20190522,,OT,BR,BR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hydrops foetalis,162666862,OT,,,162666862,1,20181214,,,,162666862,1,HIV infection
16267058,162670581,1,I,,20190430,20190502,20190502,EXP,,ZA-GILEAD-2019-0405182,GILEAD,,,,N,F,Y,,,20190502,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Corneal opacity congenital;Foetal exposure during pregnancy,162670581,OT,,,,,,,,,162670581,1,HIV infection
16269410,162694102,2,F,,20190506,20190503,20190510,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019078125,VIIV,,,,I,,Y,,,20190510,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Atrial septal defect;Ventricular septal defect,162694102,OT,,,,,,,,,162694102,1,HIV infection
16269419,162694192,2,F,,20190506,20190503,20190510,EXP,,CA-GLAXOSMITHKLINE-CA2019078125,GLAXOSMITHKLINE,,,,I,,Y,,,20190510,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Atrial septal defect;Ventricular septal defect,162694192,OT,,,,,,,,,162694192,1,HIV infection
16271657,162716571,1,I,,20190408,20190506,20190506,PER,,US-HETERO CORPORATE-HET2019US00509,HETERO,,,,,F,Y,,,20190506,,CN,US,US,Efavirenz+Lamivudine+Tenofovir,Asthenia;Feeling abnormal,,,,,,,,,,,162716571,1,Prophylaxis against HIV infection
16271660,162716601,1,I,,20190429,20190503,20190503,EXP,,GB-MYLANLABS-2019M1042031,MYLAN,,,,A,F,Y,,,20190503,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug resistance,162716601,OT,,,,,,,,,162716601,1,HIV infection
16272000,162720001,1,I,,20190429,20190506,20190506,EXP,,FR-STRIDES ARCOLAB LIMITED-2019SP003754,STRIDES,,43,YR,,F,Y,,,20190506,,OT,FR,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Hydrops foetalis,162720001,OT,,,,,,,,,162720001,1,HIV infection
16272001,162720011,1,I,,20190429,20190506,20190506,EXP,,CA-STRIDES ARCOLAB LIMITED-2019SP003753,STRIDES,,,,N,,Y,,,20190506,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162720011,OT,,,,,,,,,162720011,1,Product used for unknown indication
16274115,162741151,1,I,,20190419,20190504,20190504,EXP,,GB-MACLEODS PHARMACEUTICALS US LTD-MAC2019021082,MACLEODS,,,,,,Y,,,20190504,,OT,GB,BR,LAMIVUDINE+ EFAVIRENZ + TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Maternal exposure during pregnancy,162741151,OT,,,162741151,1,20170609,20171231,,,162741151,1,HIV infection
16279346,162793461,1,I,,20190422,20190507,20190507,EXP,,US-AUROBINDO-AUR-APL-2019-023749,AUROBINDO,,,,,,Y,,,20190507,,OT,US,US,EFAVIRENZ.,Drug interaction;Fall;Myopathy;Toxicity to various agents,162793461,HO,,,,,,,,,162793461,1,HIV infection
16280003,162800032,2,F,,20190507,20190507,20190514,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-020086",BOEHRINGER INGELHEIM,,,,N,,Y,,,20190514,,OT,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR D,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162800032,CA,,,,,,,,,162800032,1,HIV infection
16280615,162806152,2,F,,20190424,20190507,20190508,EXP,,FR-HETERO CORPORATE-HET2019FR00584,HETERO,,,,N,,Y,,,20190508,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,162806152,CA,,,162806152,1,20050513,20050908,,,162806152,1,HIV infection
16280958,162809581,1,I,,20170824,20190507,20190507,EXP,,US-MYLANLABS-2017M1055413,MYLAN,"ALI MS, KOORAGAYALU S, MBA BI, OLSEN FC. ISOLATED MYOPATHY: AN UNUSUAL MANIFESTATION OF INHALED FLUTICASONE PROPIONATE AND RITONAVIR INTERACTION. ARCHIVOS DE BRONCONEUMOLOGIA 55: 223-225, NO. 4, APR 2019",58,YR,,M,Y,,,20190507,,OT,US,US,EFAVIRENZ.,Fall;Labelled drug-drug interaction medication error;Myopathy,162809581,HO,,,,,,,,,162809581,1,Chronic obstructive pulmonary disease
16284374,162843741,1,I,,20190424,20190508,20190508,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-042035,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20190508,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,162843741,CA,,,162843741,1,20050513,20050908,,,162843741,1,Product used for unknown indication
16284485,162844852,2,F,,20190506,20190508,20190521,EXP,,CA-AUROBINDO-AUR-APL-2019-025238,AUROBINDO,,,,,,Y,,,20190521,,MD,CA,CA,Tenofovir + efavirenz + emtricitabine,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162844852,CA,,,,,,,,,162844852,1,Product used for unknown indication
16285005,162850051,1,I,,20190425,20190508,20190508,EXP,,FR-CIPLA LTD.-2019FR02875,CIPLA,,,,,,Y,,,20190508,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,162850051,OT,,,,,,,,,,,
16287246,162872462,2,F,,20190529,20190508,20190603,EXP,,PE-GILEAD-2019-0406159,GILEAD,,21,YR,A,M,Y,,,20190603,,OT,PE,PE,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,162872462,HO,,,,,,,,,162872462,1,HIV infection
16288958,162889582,2,F,,20190509,20190509,20190513,EXP,,FR-AUROBINDO-AUR-APL-2019-026163,AUROBINDO,,,,,,Y,,,20190513,,CN,FR,FR,EFAVIRENZ.,Exposure during pregnancy;Folate deficiency;Insomnia;Vertigo,162889582,OT,,,162889582,1,20050513,20050908,,,162889582,1,HIV infection
16289880,162898801,1,I,,20190425,20190509,20190509,EXP,,GB-MACLEODS PHARMACEUTICALS US LTD-MAC2019021164,MACLEODS,,,,,,Y,,,20190509,,OT,GB,FR,EFAVIRENZ.,Maternal exposure during pregnancy,162898801,OT,,,162898801,1,20050704,20050908,,,162898801,1,HIV infection
16290637,162906371,1,I,,20190425,20190509,20190509,EXP,,FR-ALVOGEN-2019-ALVOGEN-099621,ALVOGEN,,,,N,,Y,,,20190509,,MD,FR,FR,EFAVIRENZ.,Encephalocele;Foetal exposure during pregnancy;Spina bifida,162906371,OT,,,162906371,1,20050704,20050908,,,162906371,1,Product used for unknown indication
16291871,162918712,2,F,,20190506,20190509,20190516,EXP,,CA-TEVA-2019-CA-1047631,TEVA,,,,I,,Y,,,20190516,,OT,CA,CA,EFAVIRENZ+TENOFOVIR DISOPROXIL MALEATE+EMTRICITABINE GENERIC -MYLAN,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,162918712,OT,,,,,,,,,162918712,1,HIV infection
16295406,162954061,1,I,,20190425,20190509,20190509,EXP,,GB-MACLEODS PHARMACEUTICALS US LTD-MAC2019021165,MACLEODS,,,,,,Y,,,20190509,,OT,GB,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,162954061,DE,,,162954061,1,20050704,20050908,,,162954061,1,HIV infection
16297159,162971591,1,I,,20190430,20190510,20190510,EXP,,GB-MYLANLABS-2019M1043491,MYLAN,"COCKBAIN BC, MORA PERIS B, ABBARA A, SO CW, COOKE G. DISSEMINATED CMV INFECTION AND HLH IN A PATIENT WITH WELL-CONTROLLED HIV AND ULCERATIVE COLITIS. BMJ-CASE-REP 2019;12(2):227916.",50,YR,,M,Y,,,20190510,,MD,GB,GB,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Cytomegalovirus urinary tract infection;Diarrhoea;Disseminated cytomegaloviral infection;Haemophagocytic lymphohistiocytosis;Pneumonia cytomegaloviral;Proctitis bacterial;Renal impairment,162971591,HO,,,,,,,,,162971591,1,Colitis ulcerative
16297507,162975071,1,I,20181109,20190506,20190510,20190510,EXP,,GB-STRIDES ARCOLAB LIMITED-2019SP003920,STRIDES,,0,DY,,M,Y,,,20190510,,OT,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Premature baby,162975071,OT,,,,,,,,,162975071,1,Product used for unknown indication
16297508,162975081,1,I,20181109,20190506,20190510,20190510,EXP,,GB-STRIDES ARCOLAB LIMITED-2019SP003919,STRIDES,,36,YR,,F,Y,,,20190510,,OT,GB,GB,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,162975081,OT,,,,,,,,,162975081,1,Product used for unknown indication
16297534,162975341,1,I,,20190506,20190510,20190510,EXP,,GB-STRIDES ARCOLAB LIMITED-2019SP003889,STRIDES,,,,,M,Y,,,20190510,,OT,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Low birth weight baby,162975341,OT,,,,,,,,,162975341,1,Product used for unknown indication
16297606,162976064,4,F,,20190611,20190510,20190624,EXP,,ZA-AUROBINDO-AUR-APL-2019-025243,AUROBINDO,,,,,,Y,,,20190624,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Corneal opacity congenital;Foetal exposure during pregnancy,162976064,CA,,,,,,,,,162976064,1,HIV infection
16297615,162976152,2,F,,20190527,20190510,20190530,EXP,,FR-ABBVIE-19S-056-2772061-00,ABBVIE,,,,N,,Y,,,20190530,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,162976152,CA,,,,,,,,,162976152,1,Maternal exposure timing unspecified
16297818,162978183,3,F,,20190515,20190510,20190520,EXP,,FR-ABBVIE-09P-056-0558368-00,ABBVIE,,,,,,Y,,,20190517,,CN,FR,FR,EFAVIRENZ.,Anencephaly;Brain herniation;Encephalocele;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,162978183,DE,,,,,,,,,162978183,1,Maternal exposure timing unspecified
16299594,162995942,2,F,,20190606,20190510,20190607,EXP,,PE-VIIV HEALTHCARE LIMITED-PE2019GSK080906,VIIV,,21,YR,,M,Y,,,20190607,,OT,PE,PE,EFAVIRENZ.,Alopecia areata;CSF glucose decreased;CSF test abnormal;Capillary disorder;Disease recurrence;Eczema;Epidermal necrosis;Headache;Immune reconstitution inflammatory syndrome;Lacrimation increased;Lichenoid keratosis;Lymphocytic infiltration;Madarosis;Melanoderma;Neurosyphilis;Parakeratosis;Penile exfoliation;Penile ulceration;Periorbital oedema;Rash papular;Scrotal ulcer;Secondary syphilis;Skin discolouration;Skin exfoliation;Skin hyperpigmentation;Skin plaque;Uveitis;Vision blurred;Visual acuity reduced;Visual field defect;Visual impairment,162995942,HO,,,,,,,,,162995942,1,HIV infection
16299595,162995952,2,F,,20190606,20190510,20190607,EXP,,PE-GLAXOSMITHKLINE-PE2019GSK080906,GLAXOSMITHKLINE,,21,YR,,M,Y,,,20190607,,OT,PE,PE,EFAVIRENZ.,Alopecia areata;CSF glucose decreased;CSF test abnormal;Capillary disorder;Disease recurrence;Eczema;Epidermal necrosis;Headache;Immune reconstitution inflammatory syndrome;Lacrimation increased;Lichenoid keratosis;Lymphocytic infiltration;Madarosis;Melanoderma;Neurosyphilis;Parakeratosis;Penile exfoliation;Penile ulceration;Periorbital oedema;Rash papular;Scrotal ulcer;Secondary syphilis;Skin discolouration;Skin exfoliation;Skin hyperpigmentation;Skin plaque;Uveitis;Vision blurred;Visual acuity reduced;Visual field defect;Visual impairment,162995952,OT,,,,,,,,,162995952,1,HIV infection
16301963,163019632,2,F,,20190529,20190512,20190530,EXP,,PHHY2019FR107072,SANDOZ,,,,N,,Y,,,20190531,,MD,COUNTRY NOT SPECIFIED,FR,EFAVIRENZ.,Brain herniation;Encephalocele;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,163019632,DE,,,163019632,1,20050704,20050908,,,163019632,1,Foetal exposure during pregnancy
16301964,163019642,2,F,20050813,20190513,20190512,20190515,EXP,,PHHY2019FR105286,SANDOZ,,,,N,,Y,,,20190516,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,163019642,DE,,,163019642,1,20050704,20050908,,,163019642,1,Foetal exposure during pregnancy
16302622,163026221,1,I,,20190430,20190513,20190513,EXP,,GB-CIPLA LTD.-2019GB02975,CIPLA,,,,,,Y,,,20190513,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,163026221,OT,,,163026221,2,20171006,,,,163026221,1,HIV infection
16302750,163027501,1,I,,20190430,20190513,20190513,EXP,,CA-CIPLA LTD.-2019CA02972,CIPLA,,,,,,Y,,,20190513,,OT,CA,CA,EFAVIRENZ/EMTRICITABIN/TENOFOVIRDISOPROXIL MY,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,163027501,OT,,,,,,,,,,,
16303467,163034672,2,F,,20190429,20190513,20190514,EXP,,GB-HETERO-HET2019GB00641,HETERO,,43,YR,,F,Y,,,20190514,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,163034672,OT,,,163034672,1,20171006,,,,163034672,1,HIV infection
16304383,163043831,1,I,,20190509,20190513,20190513,EXP,,FR-ABBVIE-19S-056-2776233-00,ABBVIE,,,,,,Y,,,20190513,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,163043831,DE,,,,,,,,,163043831,1,Maternal exposure timing unspecified
16307804,163078041,1,I,,20190430,20190514,20190514,EXP,,CA-MACLEODS PHARMACEUTICALS US LTD-MAC2019021173,MACLEODS,,,,,,Y,,,20190514,,OT,CA,CA,EFAVIRENZ/TENOFOVIR/MALEATE/EMTRICITABINE,Maternal exposure during pregnancy,163078041,OT,,,,,,,,,163078041,1,HIV infection
16307806,163078061,1,I,,20190430,20190514,20190514,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019021174,MACLEODS,,,,,,Y,,,20190514,,OT,US,CA,EFAVIRENZ/TENOFOVIR/MALEATE/EMTRICITABINE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,163078061,OT,,,,,,,,,163078061,1,HIV infection
16308155,163081551,1,I,,20190430,20190514,20190514,EXP,,CA-ALVOGEN-2019-ALVOGEN-099727,ALVOGEN,,,,N,,Y,,,20190514,,OT,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,163081551,OT,,,,,,,,,163081551,1,Product used for unknown indication
16308301,163083011,1,I,20060216,20190506,20190514,20190514,EXP,,FR-ABBVIE-19S-056-2772098-00,ABBVIE,,25,YR,,F,Y,,,20190514,,MD,FR,FR,EFAVIRENZ.,Abortion induced;Exposure during pregnancy;Folate deficiency;Insomnia;Vertigo,163083011,OT,,,163083011,1,20050908,20050908,,,163083011,1,HIV infection
16309398,163093982,2,F,20181030,20190527,20190514,20190529,EXP,,BW-VIIV HEALTHCARE LIMITED-ZA2019GSK082902,VIIV,,72,YR,,F,Y,,,20190529,,MD,BW,BW,EFAVIRENZ.,Abdominal distension;Death;Hepatic cancer,163093982,OT,,,163093982,1,20170614,,,,163093982,1,HIV infection
16311357,163113571,1,I,,20190509,20190514,20190514,EXP,,GB-GILEAD-2019-0407153,GILEAD,,53,YR,A,M,Y,,,20190514,,CN,GB,GB,EFAVIRENZ.,Abnormal dreams;Hallucination,163113571,OT,,,163113571,1,2006,,,,163113571,1,HIV infection
16312898,163128981,1,I,,20190430,20190515,20190515,EXP,,CA-APOTEX-2019AP014514,APOTEX,,,,I,,Y,,,20190515,,CN,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,163128981,CA,,,,,,,,,163128981,1,Product used for unknown indication
16312970,163129701,1,I,,20190430,20190515,20190515,EXP,,CA-HETERO CORPORATE-HET2019CA00639,HETERO,,,,I,,Y,,,20190515,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,163129701,OT,,,,,,,,,163129701,1,HIV infection
16314485,163144851,1,I,,20190507,20190515,20190515,EXP,,NG-MYLANLABS-2019M1045681,MYLAN,"AKASE IE, OLOWOYO O, OLADELE RO, OBIAKO RO, WARRIS A, AKANMU SA. CRYPTOCOCCAL MENINGITIS AFTER ART: NEED FOR PROPER BASELINE EVALUATION IN THE ERA OF ^TEST + TREAT^. MED-MYCOL-CASE-REPORTS 2019;24:58-60.",52,YR,,M,Y,,,20190515,,OT,NG,NG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR/TENOFOVIR DISOPROXIL FUMARATE,Blindness;Facial paralysis;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Paralysis,163144851,OT,,,,,,,,,163144851,1,HIV infection
16316293,163162931,1,I,,20190510,20190515,20190515,EXP,,US-GILEAD-2019-0407096,GILEAD,,63,YR,A,M,Y,,,20190515,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Metastatic lymphoma;Prostate cancer,163162931,HO,,,,,,,,,163162931,1,HIV infection
16318287,163182871,1,I,,20190509,20190516,20190516,EXP,,MZ-VIIV HEALTHCARE LIMITED-MZ2019GSK083462,VIIV,,2,MON,,M,Y,4.2,KG,20190516,,MD,US,MZ,EFAVIRENZ.,Abdominal distension;Anaemia;Bone erosion;Bone tuberculosis;Congenital tuberculosis;Exposure via breast milk;Foetal exposure during pregnancy;Fontanelle depressed;Generalised tonic-clonic seizure;Hepatosplenomegaly;Irritability;Mass;Meningitis tuberculous;Osteopenia;Pallor;Pyrexia;Tuberculosis gastrointestinal,163182871,OT,,,,,,,,,163182871,1,Antiretroviral therapy
16318288,163182881,1,I,,20190509,20190516,20190516,EXP,,MZ-GLAXOSMITHKLINE-MZ2019GSK083462,GLAXOSMITHKLINE,,2,MON,,M,Y,4.2,KG,20190516,,MD,US,MZ,EFAVIRENZ.,Abdominal distension;Anaemia;Bone erosion;Bone tuberculosis;Congenital tuberculosis;Exposure via breast milk;Foetal exposure during pregnancy;Fontanelle depressed;Generalised tonic-clonic seizure;Hepatosplenomegaly;Irritability;Mass;Meningitis tuberculous;Osteopenia;Pallor;Pyrexia;Tuberculosis gastrointestinal,163182881,HO,,,,,,,,,163182881,1,Antiretroviral therapy
16320900,163209001,1,I,,20190509,20190516,20190516,EXP,,US-GILEAD-2019-0407404,GILEAD,,52,YR,A,M,Y,,,20190516,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alcohol poisoning;Economic problem,163209001,OT,,,,,,,,,163209001,1,HIV infection
16322153,163221531,1,I,,20190509,20190516,20190516,EXP,,MZ-GLAXOSMITHKLINE-MZ2019GSK083468,GLAXOSMITHKLINE,,3,MON,,M,Y,4.3,KG,20190516,,MD,US,MZ,EFAVIRENZ.,Anaemia;Bone erosion;Bone tuberculosis;Congenital tuberculosis;Crepitations;Exposure via breast milk;Foetal exposure during pregnancy;Hypoxia;Irritability;Lung infiltration;Mass;Osteopenia;Pallor;Pneumonia bacterial;Pulmonary tuberculosis;Pyrexia;Rales;Respiratory distress;Tachypnoea;Use of accessory respiratory muscles,163221531,OT,,,,,,,,,163221531,1,Antiretroviral therapy
16322154,163221541,1,I,,20190509,20190516,20190516,EXP,,MZ-VIIV HEALTHCARE LIMITED-MZ2019GSK083468,VIIV,,3,MON,,M,Y,4.3,KG,20190516,,MD,US,MZ,EFAVIRENZ.,Anaemia;Bone erosion;Bone tuberculosis;Congenital tuberculosis;Crepitations;Exposure via breast milk;Foetal exposure during pregnancy;Hypoxia;Irritability;Lung infiltration;Mass;Osteopenia;Pallor;Pneumonia bacterial;Pulmonary tuberculosis;Pyrexia;Rales;Respiratory distress;Tachypnoea;Use of accessory respiratory muscles,163221541,OT,,,,,,,,,163221541,1,Antiretroviral therapy
16323548,163235483,3,F,200809,20190527,20190517,20190528,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-047409,BRISTOL MYERS SQUIBB,,68,YR,,M,Y,69.5,KG,20190528,,MD,ES,ES,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE;EFAVIRENZ.",Prescribed overdose;Pulmonary tuberculosis,163235483,OT,,,163235483,1,200805,200809,,,163235483,1,HIV infection
16324255,163242551,1,I,,20190503,20190517,20190517,EXP,,CA-AUROBINDO-AUR-APL-2019-027689,AUROBINDO,,,,,,Y,,,20190517,,OT,CA,CA,SUSTIVA,Anxiety,163242551,OT,,,,,,,,,163242551,1,Psychotic disorder
16326897,163268971,1,I,20180712,20190510,20190517,20190517,EXP,FR-AFSSAPS-PC20180811,FR-MYLANLABS-2019M1046192,MYLAN,,65,YR,,F,Y,,,20190517,,PH,FR,FR,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Lactic acidosis;Metabolic acidosis;Renal failure;Septic shock;Urinary tract infection,163268971,HO,,,163268971,1,20180414,20180713,,,163268971,1,Diabetes mellitus
16336953,163369531,1,I,,20190516,20190521,20190521,EXP,,US-GILEAD-2019-0408673,GILEAD,,34,YR,A,M,Y,,,20190521,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Tooth fracture,163369531,OT,,,,,,,,,163369531,1,HIV infection
16337619,163376191,1,I,,20190517,20190521,20190521,EXP,,PHHY2019FR115204,SANDOZ,,,,,,Y,,,20190521,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida;Spinocerebellar disorder,163376191,CA,,,,,,,,,163376191,1,Foetal exposure during pregnancy
16337744,163377441,1,I,,20190506,20190521,20190521,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-044731,BRISTOL MYERS SQUIBB,,25,YR,,F,Y,,,20190521,,OT,FR,FR,EFAVIRENZ.,Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,163377441,OT,,,163377441,1,20050513,20050908,,,163377441,1,HIV infection
16337837,163378371,1,I,20180303,20190516,20190521,20190521,EXP,,GB-GILEAD-2019-0408345,GILEAD,,31,YR,A,F,Y,,,20190521,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,163378371,OT,,,,,,,,,163378371,1,HIV infection
16337993,163379931,1,I,,20190508,20190521,20190521,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-047432,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20190521,,OT,NG,NG,EFAVIRENZ.,Cryptococcosis;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,163379931,HO,,,,,,,,,163379931,1,HIV infection
16338266,163382661,1,I,,20190507,20190521,20190521,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-049395,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20190521,,OT,IT,IT,EFAVIRENZ.,Drug interaction;Virologic failure,163382661,OT,,,,,,,,,163382661,1,HIV infection
16340372,163403721,1,I,,20190509,20190522,20190522,EXP,,CO-CIPLA LTD.-2019CO03642,CIPLA,,,,,,Y,,,20190522,,OT,CO,CO,EFAVIRENZ.,Toxic skin eruption,163403721,OT,,,,,,,,,163403721,1,Antiretroviral therapy
16340534,163405341,1,I,,20190507,20190522,20190522,EXP,,CA-AUROBINDO-AUR-APL-2019-027585,AUROBINDO,,,,,,Y,,,20190522,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,163405341,OT,,,,,,,,,163405341,1,Bipolar disorder
16340539,163405391,1,I,,20190507,20190522,20190522,EXP,,CA-AUROBINDO-AUR-APL-2019-027542,AUROBINDO,,,,,,Y,,,20190522,,OT,CA,CA,SUSTIVA,Anxiety,163405391,HO,,,,,,,,,163405391,1,Depression
16341719,163417191,1,I,201012,20190513,20190522,20190522,EXP,,PT-ABBVIE-19S-130-2780428-00,ABBVIE,,,,A,F,Y,,,20190522,,MD,PT,PT,EFAVIRENZ.,Drug ineffective;Exposure during pregnancy;Renal impairment;Treatment noncompliance;Viral load increased,163417191,OT,,,163417191,1,201006,201012,,,163417191,1,HIV infection
16341890,163418901,1,I,,20190510,20190522,20190522,EXP,,FR-TEVA-2019-FR-1051408,TEVA,,46,YR,,F,Y,,,20190522,,PH,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL,Blister;Face oedema;Purulence;Swelling face,163418901,OT,,,,,,,,,,,
16344287,163442871,1,I,201804,20190514,20190522,20190522,EXP,FR-AFSSAPS-TO20184266,FR-MYLANLABS-2019M1047609,MYLAN,,,,,,Y,,,20190522,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Kidney malformation,163442871,CA,,,163442871,1,20180417,20180706,,,163442871,1,Product used for unknown indication
16344775,163447751,1,I,,20190513,20190522,20190522,EXP,,CA-TEVA-2019-CA-1051062,TEVA,,,,,,Y,,,20190522,,OT,CA,CA,MYLANEFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,163447751,CA,,,,,,,,,163447751,1,HIV infection
16346032,163460322,2,F,20171006,20190529,20190523,20190605,EXP,,GB-TEVA-2019-GB-1052525,TEVA,,43,YR,,F,Y,,,20190605,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,163460322,OT,,,,,,,,,163460322,1,Supplementation therapy
16346040,163460402,2,F,,20190527,20190523,20190603,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-046204,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190603,,CN,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrops foetalis,163460402,OT,,,163460402,2,20171006,,,,163460402,1,Product used for unknown indication
16346211,163462111,1,I,,20190508,20190523,20190523,EXP,,CA-AUROBINDO-AUR-APL-2019-028403,AUROBINDO,,,,,,Y,,,20190523,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,163462111,OT,,,,,,,,,163462111,1,HIV infection
16346235,163462352,2,F,,20190625,20190523,20190629,EXP,,CA-AUROBINDO-AUR-APL-2019-027597,AUROBINDO,,,,,,Y,,,20190629,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,163462352,OT,,,,,,,,,163462352,1,HIV infection
16347125,163471252,2,F,,20190527,20190523,20190603,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-049516,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20190603,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,163471252,OT,,,163471252,2,20171006,,,,163471252,1,HIV infection
16351614,163516141,1,I,,20190513,20190524,20190524,EXP,,NG-HETERO CORPORATE-HET2019NG00720,HETERO,"AKASE IE, OLOWOYO O, OLADELE RO, OBIAKO RO, WARRIS A, AKANMU SA. CRYPTOCOCCAL MENINGITIS AFTER ART: NEED FOR PROPER BASELINE EVALUATION IN THE ERA OF ?TEST + TREAT?. MEDICAL MYCOLOGY CASE REPORTS. 2019;24:58-60",52,YR,,M,Y,,,20190524,,OT,NG,NG,Efavirenz+Lamivudine+Tenofovir,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,163516141,HO,,,,,,,,,163516141,1,HIV infection
16351796,163517961,1,I,,20190520,20190524,20190524,EXP,,NG-AUROBINDO-AUR-APL-2019-030291,AUROBINDO,,,,,,Y,,,20190524,,OT,NG,NG,"Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate",Blindness;Blood HIV RNA increased;Blood pressure increased;CSF protein increased;Diplopia;Facial paralysis;Facial paresis;Headache;Kernig's sign;Meningitis cryptococcal;Musculoskeletal stiffness;Pallor;Papilloedema;Paralysis;Photophobia;Pyrexia;Restlessness;Sluggishness;Vision blurred;Visual impairment,163517961,OT,,,,,,,,,163517961,1,HIV antibody positive
16354407,163544071,1,I,200809,20190513,20190524,20190524,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-047790,BRISTOL MYERS SQUIBB,,68,YR,,M,Y,69.5,KG,20190524,,MD,ES,ES,EFAVIRENZ.,Pulmonary tuberculosis,163544071,OT,,,163544071,1,200311,200809,,,163544071,1,HIV infection
16354669,163546691,1,I,,20060113,20190524,20190524,EXP,,CA-PFIZER INC-13266,PFIZER,,,,,M,Y,,,20190524,,OT,CA,CA,EFAVIRENZ.,Congenital eyelid malformation;Congenital nose malformation;Deafness bilateral;Dysmorphism;Eyelid ptosis congenital;Hypertelorism of orbit;Maternal exposure during pregnancy;Radioulnar synostosis;Skull malformation;Synostosis,163546691,CA,,,,,,,,,163546691,1,Vulvovaginal candidiasis
16356995,163569951,1,I,,20190515,20190527,20190527,EXP,,UG-CIPLA LTD.-2019UG03919,CIPLA,,,,,,Y,,,20190527,,OT,US,UG,EFAVIRENZ.,Death;Exposure during pregnancy,163569951,DE,,,163569951,1,20130723,20131121,,,163569951,1,HIV infection
16358435,163584351,1,I,20110407,20181206,20190527,20190527,EXP,,FR-GLAXOSMITHKLINE-FR2018223061,GLAXOSMITHKLINE,,51,YR,,F,Y,,,20190527,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Treatment failure;Viral mutation identified,163584351,OT,,,,,,,,,163584351,1,HIV infection
16358437,163584371,1,I,20110407,20181206,20190527,20190527,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018223061,VIIV,,51,YR,,F,Y,,,20190527,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Treatment failure;Viral mutation identified,163584371,OT,,,,,,,,,163584371,1,HIV infection
16360719,163607192,2,F,201006,20190521,20190528,20190604,EXP,,PT-AUROBINDO-AUR-APL-2019-029299,AUROBINDO,,,,,,Y,,,20190604,,MD,PT,PT,EFAVIRENZ.,Drug ineffective;Maternal exposure during pregnancy;Renal impairment;Treatment noncompliance;Viral load increased,163607192,OT,,,163607192,1,201006,201012,,,163607192,1,HIV infection
16361013,163610131,1,I,,20190513,20190528,20190528,EXP,,NL-AUROBINDO-AUR-APL-2019-028955,AUROBINDO,,,,,,Y,,,20190528,,OT,NL,NL,EFAVIRENZ.,Neuropsychiatric symptoms,163610131,OT,,,,,,,,,163610131,1,HIV infection
16362120,163621201,1,I,,20180508,20190528,20190528,EXP,,DE-MYLANLABS-2018M1031472,MYLAN,"MULU A, MAIER M, LIEBERT U. ETAL.. UPWARD TRENDS OF ACQUIRED DRUG RESISTANCES IN ETHIOPIAN HIV-1C ISOLATES: OCT 19:E0186619.. A DECADE LONGITUDINAL STUDY. 2017;12:10",25,YR,,F,Y,,,20190528,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Viral mutation identified,163621201,OT,,,,,,,,,163621201,1,Product used for unknown indication
16362389,163623892,2,F,,20190612,20190528,20190618,PER,,US-PFIZER INC-2019221438,PFIZER,,50,YR,,M,Y,,,20190618,,MD,US,US,EFAVIRENZ.,Drug hypersensitivity,,,,,,,,,,,,,
16363321,163633211,1,I,,20190517,20190528,20190528,EXP,,FR-MYLANLABS-2019M1048515,MYLAN,"CORBIN V, FRANGE P, VEBER F, BLANCHE S, RUNEL-BELLIARD C, LALANDE M, ET AL.. CLINICAL, VIROLOGICAL AND IMMUNOLOGICAL FEATURES OF HIV-POSITIVE CHILDREN INTERNATIONALLY ADOPTED IN FRANCE FROM 2005-2015. PLOS ONE.. 2018;13(9):E0203438",3,YR,,,Y,,,20190528,,OT,FR,FR,EFAVIRENZ.,Virologic failure,163633211,OT,,,,,,,,,163633211,1,HIV infection
16365955,163659551,1,I,201012,20190514,20190529,20190529,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-048083,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20190529,,MD,PT,PT,EFAVIRENZ.,Drug ineffective;Maternal exposure during pregnancy;Renal impairment;Treatment noncompliance;Viral load increased,163659551,OT,,,163659551,1,200905,201012,,,163659551,1,HIV infection
16369908,163699081,1,I,,20190522,20190530,20190530,EXP,,CA-TEVA-2019-CA-1055283,TEVA,,60,YR,,M,Y,81.72,KG,20190530,,MD,CA,CA,TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Abdominal discomfort;Nausea,163699081,DS,,,,,,,,,163699081,1,HIV test positive
16370095,163700952,2,F,,20190524,20190530,20190612,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-048913,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20190612,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,163700952,OT,,,163700952,1,20171006,,,,163700952,1,HIV infection
16372667,163726671,1,I,,20190518,20190530,20190530,EXP,,CA-APOTEX-2019AP014810,APOTEX,,45,YR,,M,Y,,,20190530,,CN,CA,CA,EFAVIRENZ.,Bone pain;Hypophosphataemia;Musculoskeletal deformity;Osteomalacia;Renal tubular dysfunction,163726671,DS,,,,,,,,,163726671,1,HIV infection
16375402,163754021,1,I,,20190522,20190531,20190531,EXP,,NG-APPCO PHARMA LLC-2067630,APPCO PHARMA,,52,YR,,M,Y,,,20190531,,OT,NG,NG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal,163754021,LT,,,,,,,,,163754021,1,HIV antibody positive
16376493,163764931,1,I,20110407,20190516,20190531,20190531,EXP,,FR-AUROBINDO-AUR-APL-2019-031186,AUROBINDO,,,,,,Y,,,20190531,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Treatment failure;Viral mutation identified,163764931,OT,,,,,,,,,163764931,1,HIV infection
16385324,163853241,1,I,,20190524,20190603,20190603,EXP,,UG-MYLANLABS-2019M1051575,MYLAN,,,,A,,Y,,,20190603,,MD,DE,UG,EFAVIRENZ.,Treatment failure,163853241,OT,,,,,,,,,163853241,1,HIV infection
16390637,163906371,1,I,,20190522,20190604,20190604,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-051187,BRISTOL MYERS SQUIBB,,68,YR,,M,Y,,,20190604,,MD,GB,GB,EFAVIRENZ.,Cardiovascular disorder,163906371,OT,,,,,,,,,163906371,1,HIV infection
16392710,163927102,2,F,20051226,20190529,20190605,20190614,EXP,,US-VIIV HEALTHCARE LIMITED-A0868257A,VIIV,,,,N,,Y,,,20190614,,OT,COUNTRY NOT SPECIFIED,US,SUSTIVA,Foetal exposure during pregnancy;Plagiocephaly,163927102,CA,,,,,,,,,163927102,1,HIV infection
16392728,163927282,2,F,20051226,20190529,20190605,20190614,EXP,,US-GLAXOSMITHKLINE-A0868257A,GLAXOSMITHKLINE,,,,N,,Y,,,20190614,,OT,COUNTRY NOT SPECIFIED,US,SUSTIVA,Foetal exposure during pregnancy;Plagiocephaly,163927282,CA,,,,,,,,,163927282,1,HIV infection
16392757,163927571,1,I,,20190528,20190605,20190605,EXP,,GB-TEVA-2019-GB-1057581,TEVA,,43,YR,,F,Y,,,20190605,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,163927571,OT,,,163927571,2,20171006,,,,163927571,1,HIV infection
16394356,163943564,4,F,20180802,20190611,20190605,20190614,EXP,,DE-GILEAD-2019-0411767,GILEAD,,40,YR,A,M,Y,92,KG,20190614,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depression,163943564,OT,,,163943564,10,20141012,20181121,,,163943564,1,HIV infection
16400656,164006561,1,I,,20190522,20190606,20190606,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-055536,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190606,,OT,GB,GB,EFAVIRENZ.,Congenital toxoplasmosis;Foetal exposure during pregnancy,164006561,OT,,,,,,,,,164006561,1,Product used for unknown indication
16400657,164006571,1,I,,20190522,20190606,20190606,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-051889,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,,,20190606,,OT,GB,GB,EFAVIRENZ.,Alanine aminotransferase increased;C-reactive protein increased;Maternal exposure during pregnancy;Pyrexia,164006571,OT,,,,,,,,,164006571,1,Antiretroviral therapy
16401859,164018591,1,I,,20190522,20190607,20190607,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-055537,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20190607,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,164018591,OT,,,,,,,,,164018591,1,HIV infection
16402847,164028471,1,I,,20190604,20190607,20190607,EXP,,US-GILEAD-2019-0411788,GILEAD,,,,A,F,Y,,,20190607,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,164028471,HO,,,,,,,,,164028471,1,HIV infection
16403552,164035521,1,I,,20190523,20190607,20190607,EXP,,IT-AUROBINDO-AUR-APL-2019-031588,AUROBINDO,,,,,,Y,,,20190607,,OT,IT,IT,EFAVIRENZ.,Drug interaction;Virologic failure,164035521,OT,,,,,,,,,164035521,1,HIV infection
16411782,164117821,1,I,,20190530,20190610,20190610,EXP,,IN-MYLANLABS-2019M1053778,MYLAN,,42,YR,,M,Y,,,20190610,,MD,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Immune reconstitution inflammatory syndrome;Pneumocystis jirovecii pneumonia;Respiratory failure,164117821,OT,,,,,,,,,164117821,1,HIV infection
16413410,164134101,1,I,,20190529,20190611,20190611,EXP,,CN-LUPIN PHARMACEUTICALS INC.-2019-03507,LUPIN,,,,,,Y,,,20190611,,OT,CN,CN,EFAVIRENZ.,Drug-induced liver injury,164134101,OT,,,,,,,,,164134101,1,Product used for unknown indication
16424708,164247081,1,I,,20190603,20190613,20190613,EXP,,ZA-AUROBINDO-AUR-APL-2019-034382,AUROBINDO,,,,,,Y,,,20190613,,MD,ZA,ZA,EFAVIRENZ.,Skin reaction;Transaminases increased,164247081,HO,,,,,,,,,164247081,1,Product used for unknown indication
16424709,164247091,1,I,,20190603,20190613,20190613,EXP,,ZA-AUROBINDO-AUR-APL-2019-034383,AUROBINDO,,,,,,Y,,,20190613,,MD,ZA,ZA,EFAVIRENZ.,Hepatic enzyme increased;Skin reaction;Transaminases increased,164247091,LT,,,,,,,,,164247091,1,Product used for unknown indication
16426280,164262801,1,I,,20190610,20190613,20190613,PER,,US-GILEAD-2019-0413042,GILEAD,,64,YR,A,M,Y,,,20190613,,CN,US,US,SUSTIVA,Nightmare,,,,,164262801,1,2004,,,,164262801,1,HIV infection
16428713,164287131,1,I,,20190610,20190613,20190613,EXP,,MY-GILEAD-2019-0413166,GILEAD,"IBRAHIMI N, KOHI K. A CASE OF RHODOCOCCUS IMMUNE RECONSTITUTION SYNDROME (IRIS) IN A PATIENT WITH HIV INFECTION. 4TH INTERNATIONAL CONFERENCE ON TROPICAL MEDICINE AND INFECTIOUS DISEASES(CTMID). 2019;UNK:UNK",38,YR,A,M,Y,,,20190613,,OT,MY,MY,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Pneumonia bacterial,164287131,OT,,,,,,,,,164287131,1,HIV infection
16434575,164345751,1,I,,20190611,20190614,20190614,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK105248,VIIV,,54,YR,,M,Y,,,20190614,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164345751,OT,,,,,,,,,164345751,1,HIV infection
16434585,164345851,1,I,,20190611,20190614,20190614,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK105248,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20190614,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164345851,OT,,,,,,,,,164345851,1,HIV infection
16437282,164372821,1,I,,20190613,20190615,20190615,EXP,,CA-009507513-1906CAN005474,MERCK,,54,YR,,M,Y,,,20190615,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164372821,OT,,,,,,,,,164372821,1,HIV infection
16438510,164385101,1,I,,20190611,20190617,20190617,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK106137,VIIV,,,,,M,Y,,,20190617,,OT,CA,CA,EFAVIRENZ.,Depression;Drug interaction,164385101,OT,,,,,,,,,164385101,1,Product used for unknown indication
16438515,164385151,1,I,,20190611,20190617,20190617,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK106137,GLAXOSMITHKLINE,,,,,M,Y,,,20190617,,OT,CA,CA,EFAVIRENZ.,Depression;Drug interaction,164385151,OT,,,,,,,,,164385151,1,Product used for unknown indication
16439328,164393281,1,I,,20190611,20190617,20190617,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK106136,VIIV,,,,,M,Y,,,20190617,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164393281,OT,,,,,,,,,164393281,1,Product used for unknown indication
16439329,164393291,1,I,,20190611,20190617,20190617,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK106102,VIIV,,52,YR,,M,Y,,,20190617,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,164393291,OT,,,,,,,,,164393291,1,HIV infection
16439335,164393351,1,I,,20190611,20190617,20190617,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK106136,GLAXOSMITHKLINE,,,,,M,Y,,,20190617,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164393351,OT,,,,,,,,,164393351,1,Product used for unknown indication
16439340,164393401,1,I,,20190611,20190617,20190617,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK106102,GLAXOSMITHKLINE,,52,YR,,M,Y,,,20190617,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,164393401,CA,,,,,,,,,164393401,1,HIV infection
16439860,164398601,1,I,,20190613,20190617,20190617,EXP,,CA-009507513-1906CAN005466,MERCK,,,,,M,Y,,,20190617,,OT,CA,CA,EFAVIRENZ.,Depression;Drug interaction,164398601,OT,,,,,,,,,164398601,1,Product used for unknown indication
16441111,164411111,1,I,201112,20190610,20190617,20190617,EXP,,GB-MYLANLABS-2019M1056682,MYLAN,,,,A,M,Y,,,20190617,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Osteoporosis,164411111,OT,,,164411111,1,201112,201810,,,164411111,1,HIV infection
16443892,164438921,1,I,,20190603,20190618,20190618,EXP,,CA-AUROBINDO-AUR-APL-2019-033424,AUROBINDO,,,,,,Y,,,20190618,,OT,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,164438921,HO,,,,,,,,,164438921,1,Psychotic disorder
16444101,164441011,1,I,,20190611,20190618,20190618,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK106134,VIIV,,54,YR,,M,Y,,,20190618,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164441011,OT,,,,,,,,,164441011,1,Product used for unknown indication
16444104,164441041,1,I,,20190611,20190618,20190618,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK106134,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20190618,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164441041,OT,,,,,,,,,164441041,1,Product used for unknown indication
16444785,164447851,1,I,201805,20190611,20190618,20190618,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-058554,BRISTOL MYERS SQUIBB,,63,YR,,M,Y,111.13,KG,20190618,,CN,US,US,EFAVIRENZ.,Depression;Mental disorder;Substance abuse,164447851,HO,,,164447851,1,1999,,,,164447851,1,HIV infection
16446145,164461451,1,I,,20190611,20190618,20190618,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK105240,VIIV,,54,YR,,M,Y,,,20190618,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164461451,OT,,,,,,,,,164461451,1,HIV infection
16446146,164461461,1,I,,20190611,20190618,20190618,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK105235,VIIV,,54,YR,,M,Y,,,20190618,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164461461,OT,,,,,,,,,164461461,1,HIV infection
16446149,164461491,1,I,,20190611,20190618,20190618,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK106131,VIIV,,54,YR,,M,Y,,,20190618,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164461491,OT,,,,,,,,,164461491,1,HIV infection
16446152,164461521,1,I,,20190611,20190618,20190618,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK105240,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20190618,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164461521,OT,,,,,,,,,164461521,1,HIV infection
16446153,164461531,1,I,,20190611,20190618,20190618,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK105235,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20190618,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164461531,OT,,,,,,,,,164461531,1,HIV infection
16446177,164461771,1,I,,20190611,20190618,20190618,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK106131,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20190618,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,164461771,OT,,,,,,,,,164461771,1,HIV infection
16446422,164464221,1,I,,20190611,20190618,20190618,EXP,,US-GILEAD-2019-0413810,GILEAD,,54,YR,A,M,Y,,,20190618,,CN,US,US,SUSTIVA,Depression;Mental disorder,164464221,HO,,,164464221,2,1999,,,,164464221,1,HIV infection
16447308,164473081,1,I,,20190603,20190618,20190618,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-059337,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190618,,MD,US,US,EFAVIRENZ.,Congenital central nervous system anomaly;Foetal exposure during pregnancy,164473081,CA,,,,,,,,,164473081,1,Product used for unknown indication
16447310,164473101,1,I,,20190603,20190618,20190618,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-057270,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190618,,MD,US,US,EFAVIRENZ.,Arnold-Chiari malformation;Congenital hydrocephalus;Foetal exposure during pregnancy;Meningomyelocele,164473101,CA,,,,,,,,,164473101,1,Product used for unknown indication
16447375,164473751,1,I,,20190605,20190619,20190619,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-056308,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20190619,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,164473751,OT,,,164473751,1,20171006,,,,164473751,1,HIV infection
16450813,164508131,1,I,,20190611,20190619,20190619,EXP,,US-GILEAD-2019-0413976,GILEAD,,54,YR,A,M,Y,111.11,KG,20190619,,CN,US,US,SUSTIVA,Mental disorder,164508131,HO,,,,,,,,,164508131,1,Product used for unknown indication
16454218,164542181,1,I,201808,20190610,20190619,20190619,EXP,PT-INFARMED-J201812-1031,PT-MYLANLABS-2019M1057186,MYLAN,,45,YR,,M,Y,,,20190619,,PH,PT,PT,EFAVIRENZ.,Insomnia;Nightmare,164542181,OT,,,164542181,1,20130702,20181217,,,164542181,1,HIV infection
16457895,164578951,1,I,20181116,20181123,20190620,20190620,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2018GSK214194,VIIV,,19,YR,,F,Y,46.9,KG,20190620,,MD,ZW,ZW,EFAVIRENZ.,Exposure during pregnancy;Pneumonia,164578951,HO,,,164578951,1,20170321,20181123,,,164578951,1,HIV infection
16457897,164578971,1,I,20181116,20181123,20190620,20190620,EXP,,ZW-GLAXOSMITHKLINE-ZW2018GSK214194,GLAXOSMITHKLINE,,19,YR,,F,Y,46.9,KG,20190620,,MD,ZW,ZW,EFAVIRENZ.,Exposure during pregnancy;Pneumonia,164578971,HO,,,164578971,1,20170321,20181123,,,164578971,1,HIV infection
16461189,164611892,2,F,,20190624,20190621,20190626,EXP,,CO-AUROBINDO-AUR-APL-2019-036353,AUROBINDO,"RODRIGUEZ-HERRERA D, ET AL. CISPLATIN/EFAVIRENZ/FLUOROURACIL: TOXICODERMA AND HERPES SIMPLEX VIRUS TYPE 1 INFECTION: CASE REPORT. REACTIONS WEEKLY. 2019;1757:P87",,,,,Y,,,20190626,,OT,CO,CO,EFAVIRENZ.,Toxic skin eruption,164611892,OT,,,164611892,3,201609,,,,164611892,1,HIV infection
16464279,164642791,1,I,,20190617,20190621,20190621,EXP,,IN-GILEAD-2019-0414307,GILEAD,"KUMAR V, SINGH J. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS. JOURNAL OF GLOBAL INFECTIOUS DISEASES. 2019;11:73-79. DOI:10.4103/JGID.JGID_160_18",,,A,,Y,,,20190621,,OT,IN,IN,EFAVIRENZ.,Osteoporosis,164642791,OT,,,,,,,,,164642791,1,HIV infection
16464348,164643481,1,I,,20190617,20190621,20190621,EXP,,IN-GILEAD-2019-0414308,GILEAD,"KUMAR V, SINGH J. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS. JOURNAL OF GLOBAL INFECTIOUS DISEASES. 2019;11:73-79. DOI:10.4103/JGID.JGID_160_18",,,A,,Y,,,20190621,,OT,IN,IN,EFAVIRENZ.,Osteoporosis,164643481,OT,,,,,,,,,164643481,1,HIV infection
16465683,164656831,1,I,20181101,20190613,20190621,20190621,EXP,,UG-MYLANLABS-2019M1058215,MYLAN,,33,YR,,F,Y,,,20190621,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Exposure during pregnancy;Foetal death,164656831,OT,,,164656831,1,20170724,,,,164656831,1,HIV infection
16466886,164668861,1,I,,20190610,20190624,20190624,EXP,,GB-AUROBINDO-AUR-APL-2019-034454,AUROBINDO,,,,,,Y,,,20190624,,OT,GB,GB,EFAVIRENZ.,Congenital toxoplasmosis;Foetal exposure during pregnancy,164668861,DE,,,,,,,,,164668861,1,Product used for unknown indication
16466893,164668931,1,I,,20190610,20190624,20190624,EXP,,GB-AUROBINDO-AUR-APL-2019-034451,AUROBINDO,,,,,,Y,,,20190624,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,164668931,OT,,,,,,,,,164668931,1,HIV infection
16467469,164674691,1,I,,20190610,20190624,20190624,EXP,,GB-AUROBINDO-AUR-APL-2019-034453,AUROBINDO,,,,,,Y,,,20190624,,OT,GB,GB,EFAVIRENZ.,Alanine aminotransferase increased;C-reactive protein increased;Maternal exposure during pregnancy;Pyrexia,164674691,OT,,,,,,,,,164674691,1,Antiretroviral therapy
16470765,164707651,1,I,,20190617,20190624,20190624,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019112936,VIIV,"KUMAR V, SINGH J. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES. 2019;11:73-79",,,A,,Y,,,20190624,,OT,IN,IN,EFAVIRENZ.,Osteoporosis,164707651,OT,,,,,,,,,164707651,1,HIV infection
16470766,164707661,1,I,,20190617,20190624,20190624,EXP,,IN-GLAXOSMITHKLINE-IN2019112936,GLAXOSMITHKLINE,"KUMAR V, SINGH J. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES. 2019;11:73-79",,,A,,Y,,,20190624,,OT,IN,IN,EFAVIRENZ.,Osteoporosis,164707661,OT,,,,,,,,,164707661,1,HIV infection
16470787,164707871,1,I,,20190613,20190624,20190624,EXP,,UG-MYLANLABS-2019M1058214,MYLAN,,20,YR,,F,Y,,,20190624,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Exposure during pregnancy;Foetal death,164707871,OT,,,164707871,1,20141022,,,,164707871,1,HIV infection
16473304,164733041,1,I,,20190617,20190625,20190625,EXP,,IN-GLAXOSMITHKLINE-IN2019112951,GLAXOSMITHKLINE,"KUMAR V,. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES.. 2019;11:73-79",,,A,,Y,,,20190625,,OT,IN,IN,EFAVIRENZ.,Hepatitis,164733041,OT,,,,,,,,,164733041,1,HIV infection
16473307,164733071,1,I,,20190617,20190625,20190625,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019112935,VIIV,"KUMAR V, SINGH J.. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES.. 2019;11:73-79",,,A,,Y,,,20190625,,OT,IN,IN,EFAVIRENZ.,Osteoporosis,164733071,OT,,,,,,,,,164733071,1,HIV infection
16473419,164734191,1,I,,20190617,20190625,20190625,EXP,,IN-GLAXOSMITHKLINE-IN2019112935,GLAXOSMITHKLINE,"KUMAR V, SINGH J.. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES.. 2019;11:73-79",,,A,,Y,,,20190625,,OT,IN,IN,EFAVIRENZ.,Osteoporosis,164734191,OT,,,,,,,,,164734191,1,HIV infection
16473421,164734211,1,I,,20190617,20190625,20190625,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019112951,VIIV,"KUMAR V,. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES.. 2019;11:73-79",,,A,,Y,,,20190625,,OT,IN,IN,EFAVIRENZ.,Hepatitis,164734211,OT,,,,,,,,,164734211,1,HIV infection
16473489,164734891,1,I,,20190610,20190625,20190625,EXP,,IN-AUROBINDO-AUR-APL-2019-035791,AUROBINDO,,,,,,Y,,,20190625,,MD,IN,IN,TENOFOVIR+LAMIVUDINE+EFAVIRENZ,Abdominal pain;Asthenia;Blood HIV RNA decreased;CD4 lymphocytes decreased;Cough;Decreased appetite;Dysphagia;Dyspnoea;Early satiety;HIV infection CDC group IV;Haemoglobin decreased;Hepatosplenomegaly;Immune reconstitution inflammatory syndrome;Leishmaniasis;Lymphadenopathy;Odynophagia;Oesophageal candidiasis;Pallor;Pancytopenia;Pneumocystis jirovecii pneumonia;Productive cough;Pyrexia;Respiratory failure;Tachycardia;Tachypnoea;Visceral leishmaniasis;Vomiting;Weight decreased,164734891,HO,,,,,,,,,164734891,1,HIV infection
16475912,164759121,1,I,1996,20190617,20190625,20190625,EXP,,IT-MYLANLABS-2019M1058328,MYLAN,"LANZAFAME M, LATTUADA E, RIZZARDO S, PIACENTINI D, CHIESI S, MAZZI R.. DOLUTEGRAVIR MONOTHERAPY^S VIROLOGICAL EFFICACY IN A HIGHLY TREATMENT-EXPERIENCED PATIENT.. AIDS RESEARCH AND HUMAN RETROVIRUSES.. 2019",74,YR,,F,Y,,,20190625,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Genotype drug resistance test negative;Treatment failure;Treatment noncompliance;Virologic failure,164759121,OT,,,164759121,1,2002,201502,,,164759121,1,HIV infection
16476887,164768871,1,I,,20190617,20190626,20190626,EXP,,IN-GLAXOSMITHKLINE-IN2019112949,GLAXOSMITHKLINE,"KUMAR V, SINGH J.. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES.. 2019;11:73-79",,,A,,Y,,,20190626,,OT,IN,IN,EFAVIRENZ.,Hepatitis,164768871,OT,,,,,,,,,164768871,1,HIV infection
16476893,164768931,1,I,,20190617,20190626,20190626,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019112949,VIIV,"KUMAR V, SINGH J.. A PROSPECTIVE STUDY ON IMPACT OF EARLY INITIATION OF ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE ADULTS ON IMMUNOLOGICAL STATUS AND ADVERSE EVENTS.. JOURNAL OF GLOBAL INFECTIOUS DISEASES.. 2019;11:73-79",,,A,,Y,,,20190626,,OT,IN,IN,EFAVIRENZ.,Hepatitis,164768931,OT,,,,,,,,,164768931,1,HIV infection
16477356,164773561,1,I,,20190617,20190626,20190626,EXP,,DK-HETERO-HET2019DK00859,HETERO,"LETH S, JENSEN-FANGEL S. INFRAPATELLAR BURSITIS WITH MYCOBACTERIUM MALMOENSE RELATED TO IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN HIV-POSITIVE PATIENT. BMJ-CASE-REP. 2012",39,YR,,M,Y,,,20190626,,OT,DK,DK,EFAVIRENZ.,Bursitis;Immune reconstitution inflammatory syndrome,164773561,HO,,,,,,,,,164773561,1,HIV infection
16479805,164798051,1,I,200109,20190617,20190626,20190626,EXP,,FR-MYLANLABS-2019M1057619,MYLAN,"UNAL G, MOUREZ T, LEOZ M, ALESSANDRI-GRADT E, GUILLOU-GUILLEMETTE HL, CHENNEBAULT JM ET AL. FIRST REPORT OF TRANSMISSION OF A HIGHLY RESISTANT STRAIN OF HIV-1 GROUP O. AIDS. 2016;30(16):2565-2568. DOI: 10.1097/QAD.0000000000001253.",,,,F,Y,,,20190626,,,COUNTRY NOT SPECIFIED,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,164798051,OT,,,,,,,,,164798051,1,HIV infection
16487549,164875491,1,I,2017,20190616,20190627,20190627,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-059258,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190627,,CN,US,US,SUSTIVA,Depression;Neoplasm malignant;Suicidal ideation,164875491,OT,,,,,,,,,164875491,1,HIV infection
16489848,164898481,1,I,,20190619,20190628,20190628,EXP,,ZA-CIPLA LTD.-2019ZA04670,CIPLA,,,,,,Y,,,20190628,,OT,ZA,ZA,EFAVIRENZ.,Exposure during pregnancy;Haemoglobin decreased;Platelet count decreased;Ventricular extrasystoles;Vitamin B12 deficiency,164898481,OT,,,164898481,1,20180214,,,,164898481,1,HIV infection
16494843,164948431,1,I,201906,20190625,20190628,20190628,EXP,,US-GILEAD-2019-0415427,GILEAD,,64,YR,A,M,Y,,,20190628,,CN,US,US,SUSTIVA,Amnesia;Anal cancer;Anxiety;Arthralgia;Colorectal cancer;Diarrhoea;Disturbance in attention;Gait disturbance;Gastrointestinal disorder;HIV-associated neurocognitive disorder;Insomnia;Laboratory test abnormal;Lipids abnormal;Nightmare;Osteopenia;Pain in extremity;Stevens-Johnson syndrome;Tinnitus,164948431,OT,,,164948431,1,201903,,,,164948431,1,HIV infection
6798575,67985752,2,F,,20190515,20081029,20190528,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14385819,BRISTOL MYERS SQUIBB,,45,YR,,F,Y,43,KG,20190528,,MD,US,US,EFAVIRENZ.,Drug level increased;Status epilepticus,67985752,OT,,,,,,,,,67985752,1,HIV infection
6870587,68705874,4,F,20060602,20190604,20081231,20190617,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14457303,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20190617,,CN,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,68705874,HO,,,68705874,2,20060602,20070522,,,68705874,1,HIV infection
6927324,69273247,7,F,20050813,20190521,20090304,20190522,EXP,,FR-GILEAD-2009-0020445,GILEAD,,,,,F,Y,1.19,KG,20190522,,MD,FR,FR,SUSTIVA,Arnold-Chiari malformation;Brain herniation;Foetal exposure during pregnancy;Foetal malformation;Spina bifida;Spinocerebellar disorder,69273247,OT,,,69273247,1,20050523,20060216,,,69273247,1,HIV infection
7117171,711717111,11,F,,20190508,20090917,20190514,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14780902,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20190514,,CN,US,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,711717111,OT,,,711717111,7,200802,,,,711717111,1,HIV infection
7152253,715225310,10,F,,20190514,20091019,20190517,EXP,,CA-PFIZER INC-2009279889,PFIZER,"PFEFFER, G.. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009;73 (1):71-72",52,YR,,M,Y,,,20190517,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,715225310,OT,,,,,,,,,715225310,1,HIV infection
7302622,730262231,31,F,,20190613,20100302,20190615,EXP,,CA-MERCK-0907CAN00093,MERCK,,52,YR,,M,Y,,,20190615,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,730262231,OT,,,730262231,7,200802,,,,730262231,1,HIV infection
7340650,73406502,2,F,,20190531,20090709,20190606,EXP,GB-MHRA-ADR 20065067,GB-MYLANLABS-2009S1011416,MYLAN,,57,YR,,F,Y,,,20190606,,PH,GB,GB,EFAVIRENZ.,Brain neoplasm;Drug interaction;Encephalitis;Loss of consciousness;Seizure,73406502,OT,,,73406502,1,2005,,,,73406502,1,Crohn's disease
8322070,83220702,2,F,,20170307,20120105,20190524,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-16315566,BRISTOL MYERS SQUIBB,,4,YR,,F,Y,,,20190524,,OT,ZA,ZA,EFAVIRENZ.,Drug level increased;Petit mal epilepsy,83220702,OT,,,,,,,,,83220702,1,HIV infection
